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Abstract
Background
Accurate and sensitive imaging biomarkers are required to study the progression of white matter
(WM) microglial activation in neurodegenerative diseases in vivo. The translocator protein (TSPO)
is considered a sensitive target for imaging microglial activation with positron emission
tomography (PET). This study aimed to test the ability of TSPO to detect WM microglial activation
marked by major histocompatibility complex class II (MHCII) molecules in rat models of
prodromal Alzheimer’s disease and acute subcortical stroke.
Methods
Fischer 344 wild-type (n = 12) and TgAPP21 (n = 11) rats were imaged with [18F]FEPPA PET
and MRI to investigate TSPO tracer uptake in the corpus callosum. Wild-type rats subsequently
received an endothelin-1 (ET1)-induced subcortical stroke and were imaged at days 7 and 28 poststroke before immunohistochemistry of TSPO, GFAP for astrocytes, iNOS for microglia releasing
toxic nitrous oxide, and the MHCII rat antigen, OX6.
Results
[18F]FEPPA-PET findings that TSPO expression was not increased in WM of TgAPP21 rats and
was only increased in the infarct and proximal WM were confirmed by immunohistochemistry
(infarct TSPO cells/mm2: day 7 = 555 ± 181; day 28 = 307 ± 153; proximal WMTSPO cells/mm2:
day 7 = 113 ± 93; day 28 = 5 ± 7). TSPO and iNOS were not able to detect the chronic WM
microglial activation that was detected with MHCII in the contralateral corpus callosum (day 28
OX6 % area: saline = 0.62 ± 0.38; stroke = 4.30 ± 2.83; P = .029).
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Conclusion
Within the regions and groups investigated, TSPO was only expressed in the stroke-induced insult
and proximal tissue, and therefore was unable to detect remote and non-insult-related chronically
activated microglia overexpressing MHCII in WM.
Keywords
TSPO; major histocompatibility complex class II; white matter inflammation; ischemic stroke;
Alzheimer’s disease
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Lay summary
Background
Accurate and sensitive biomarkers are required to study the progression of inflammation in
neurological diseases. To image white matter inflammation in living subjects, researchers can
produce radioactive molecules that bind to proteins in the body that serve as markers of
inflammation, inject them into the subject, then image them with positron emission tomography
(PET). Our group set out to investigate whether a protein known as the translocator protein can be
detected, in living subjects, in a type of white matter inflammation that we previously associated
with Alzheimer’s disease and deep stroke and can currently only be imaged after death. We
hypothesized that the translocator protein expression can be detected in rats with Alzheimer’s
Disease at the white matter and in rats with deep stroke at white matter that was distant from the
stroke.
Methods
Rats that were non-genetically modified (n = 12) and genetically modified to express a protein
associated with Alzheimer’s Disease (n = 11) were injected with the radioactive molecule
[18F]FEPPA to image the translocator protein using PET. After initial assessment of white matter
inflammation, the non-genetically modified rats received a deep stroke and were imaged again at
days 7 and 28 post-stroke. The rats were sacrificed to investigate their expression of the
translocator protein, other inflammatory proteins, and a protein that indicates our target
inflammation, OX6.
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Results
[18F]FEPPA positron emission tomography only detected inflammation in the stroke region of rats
that received the deep stroke; the distant white matter inflammation we wanted to image was not
detected. Inflammation was detected in distant white matter using post-mortem microscopy of the
inflammatory molecule OX6, but it was not detectable using the translocator protein, irrespective
of the binding molecule used.
Conclusion
Within the regions and groups investigated, the translocator protein was only able to detect
inflammation near the stroke region, and therefore was not able to detect the distant and noninjury-related yet pathologically important white matter inflammation that we wanted to detect.
To detect that white matter inflammation with PET, new radioactive molecules will need to be
developed.
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Chapter 1: Introduction
Chronic white matter (WM) inflammation can be observed in subcortical stroke, traumatic brain
injury, schizophrenia, and Alzhiemer’s Disease (AD) [1–4]. In particular, chronic WM
microglial activation marked by major histocompatibility complex class II (MHCII) molecules is
believed to play an early neurotoxic role [5]. To further our understanding, develop therapeutic
approaches, and aid early diagnosis, there is a need to quantify WM MHCII microglial activation
in living people. Still, there is no established method for the in vivo quantification of WM
MHCII microglial activation. In this thesis, the objective was to image chronic WM MHCII
microglial activation in vivo using translocator protein positron emission tomography (TSPOPET) in rat models of AD and subcortical stroke. The following introduction presents evidence
for why MHCII microglial activation may play a neurotoxic role in AD and subcortical stroke
and background for TSPO and PET.
1.1 White Matter (WM) Importance and Function
In vertebrates, brain WM is an important constituent of neuronal networks, which are widely
accepted as responsible for motor movement, thoughts, and meaningful behavior [6]. An
individual neuron in the networks is composed of a cell body, axons that protrude from the cell
body, and dendrites. In the central nervous system (CNS), oligodendrocytes support and wrap
axons with multiple layers of myelin. Myelinated axons appear white and therefore form the
structure known as WM. By wrapping the entire length of axons except for interspaced nodes with
myelin, nerve impulses made up of sodium and potassium ions are forced to occur only at the
nodes instead of throughout the entire axon. This is known as saltatory conduction and it makes
neuron-neuron communication more rapid by increasing the charge difference along the axonal
cytoplasm, which is often called action potential [7]. When myelin is lost, the results include a
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reduction in conduction velocity, nerve impulses become less temporally predictable, and nerve
impulses often do not lead to downstream activation [7]. As myelin is the main component of white
matter, healthy WM is essential for healthy cognitive and motor function.
1.2 Inflammation and Microglial Activation
In general, inflammation can be acute or chronic after an injury, pathogen, or autoimmune
response. Acute inflammation occurs in regions that have recently been exposed to an appropriate
stimulus, and regions outside the CNS experiencing acute inflammation are influxed with fluid to
cause swelling also known as edema. This may cause pain and loss of function by stressing nearby
neuroreceptors, and an increased blood flow may cause a red appearance and a feeling of heat [8].
In contrast, chronic inflammation occurs late after a stimulus, and regions outside the CNS
experiencing chronic inflammation are usually only associated with changes in signalling
molecules, although the molecules are different than those in acute inflammation, and white blood
cells such as macrophages [8].
Macrophages and cells with similar lineages, such as microglia in the CNS, are often
investigated to study the state of inflammation. The term macrophage is often used to refer to a
type of peripheral cell that is able to remove pathogens, dying cells, or debris by releasing reactive
oxygen species, phagocytosis, and enzyme-mediated digestion [9]. That said, macrophages also
seem to be necessary for the healing processes of re-epithelialization, collagen deposition, and
angiogenesis [10].
Inflammation in the CNS, also known as neuroinflammation, is similar to inflammation
outside the CNS with respect to the details discussed above. Exceptions include that (i) redness,
heat, and pain are not usually reported along with acute neuroinflammation and (ii) a healthy CNS
is thought to not have macrophages; the CNS has cells with a similar lineage called microglia.
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1.2.1 Microglia
Microglia are substantial contributors to the overall health of the brain because of their importance
as the main immune cells of the CNS and prevalence; microglia comprise 10% of the CNS cellular
population [11]. Although microglia are often termed ‘resting’ when they are in their inactive state,
inactive microglia are usually mobilizing their appendages to survey their microenvironment [12].
Upon detection of a variety of cues, microglia become activated and take on roles that may be
neuroprotective or neurotoxic.
Based on whether activated microglia play a neuroprotective and anti-inflammatory role
or a neurotoxic and pro-inflammatory role, they may be classified as M2 or M1, respectively [13].
Dichotomization is an oversimplification following investigation of a variety of molecules, but it
may be practical in guiding non-specific anti-inflammatory therapy as microglia may play a variety
of roles depending on the molecules that they are expressing. Molecular markers in rats that mark
M1 microglia include iNOS, MHCII, and CD68 while those that mark M2 microglia include Arg1,
Ym1, and CD206 [14]. Examples of the neuroprotective roles that M2 microglia contribute to are
myelin repair, the removal of cellular and protein debris, and the secretion of neurotrophic factors
that prevent neural injury [13]. On the other hand, M1 microglia tend to release cytokines that
recruit more microglia whilst releasing proteases, reactive nitrogen species, and oxygen species
[13].
1.2.2 Astrocytes
Astrocytes are a major cell type in the CNS, and although they are often known for their supportive
roles, astrocytes can play a role in inflammatory processes [15]. Supportive roles that astrocytes
play include maintenance of synapses, providing energetic metabolites to neurons, forming a key
component of the blood-brain-barrier (BBB) along with pericytes and endothelial cells, and
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recycling toxic waste products such as ammonia [15]. Like microglia, astrocytes termed A2 exhibit
neuroprotective and anti-inflammatory functions such as the support of BBB repair and formation
of an astrocytic barrier to restrict the infiltration of other white blood cells whilst releasing
signalling molecules that downregulate inflammation [16]. Astrocytes can be termed as A1 when
they exhibit neurotoxic and pro-inflammatory functions such as the release of neurotoxic amounts
of glutamate whilst releasing signalling molecules that upregulate inflammation [16]. In any case,
inflammatory activation of astrocytes can be marked by overexpression of the glial acid fibrillary
protein (GFAP) [17]. An important distinction given our interest in WM is that astrocytes are
called fibrous or protoplasmic astrocytes based on their appearance and whether they are expressed
in WM or grey matter, respectively [17].
1.3 Subcortical Stroke
To contextualize subcortical stroke, it is important to first discuss strokes in general. In the context
of the brain, a stroke is when a brain region has insufficient vascular perfusion to survive [18].
Strokes are usually divided into hemorrhagic and ischemic stroke based on whether the stroke is
caused by a vascular rupture or occlusion, respectively, as these two require substantially different
treatments [18]. Additionally, treatment options in ischemic stroke depend on the time since onset,
which has led to the classification of stroke into acute (< 24 hours), subacute (24 hours to 5 days),
and chronic (> 5 days) [19]. Alternatively, strokes may be distinguished based on their location,
and therefore affected brain functions, into cortical and subcortical strokes [20].
1.3.1 Subcortical Stroke Etiology
According to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification,
subcortical strokes may be caused by small-vessel disease, large-vessel disease, or embolism [18].
Embolism or large-vessel disease such as arterial stenosis causes subcortical strokes that are larger
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than 15 mm in diameter [18]. On the other hand, subcortical strokes associated with small-vessel
disease can present as lacunar strokes that are less than 15 mm in diameter and are not caused by
embolism or arterial stenosis [18]. In general, lacunar stroke is associated with, and thought to
occur by, diffuse abnormality of small vessel endothelial cells, slight increases of BBB
permeability, and leakage of substances from the blood that are considered toxic to the brain [21].
Despite evidence for the role of endothelial cells, why lacunar stroke could have a sudden
symptomatic onset remains under investigation [21].
1.3.2 Stroke Molecular Changes
Although decreased perfusion triggers the onset of stroke, it is important to realize that there are
other downstream toxic effects. In particular, insufficient perfusion in stroke hinders the ability of
the affected region to keep up with the demand for energy from adenosine triphosphate, thereby
initiating several toxic processes [22]. These include acidosis as the body tries to generate
adenosine triphosphate by lactic acid metabolism, glutamate excitotoxicity by induction of calcium
and sodium influx and the ensuing edema, production of reactive oxygen species, reactive nitrogen
species, lipases, proteases, and nucleases, and activation of glial cells, disruption of the BBB, and
infiltration of peripheral leukocytes [22].
1.3.3 Stroke Infarct Core and Penumbra
The concept of infarct core and penumbra is important in stroke and is also relevant in subcortical
stroke. The infarct core is a region in the center of the stroke site that is non-functional and does
not have enough perfusion to survive. On the other hand, the infarct penumbra is non-functional
but, although it has a perfusion deficiency, it can be salvaged using thrombolytic therapy [23].
Salvaging the penumbra improves cognitive and functional outcome in people who experience a
stroke [23]. Between people who have lacunar and those with non-lacunar strokes, the incidence
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is the same for the detection of an infarct core and penumbra within 4.5 hours, which is 20-60%
depending on perfusion thresholds [24].
Rodent studies have shown that the neuroinflammatory cell composition differs between
the infarct core and penumbra, but this difference seems to invert with time. Histological
differentiation of the infarct core and penumbra may be accomplished using microtube-associated
protein 2 (MAP2) immunohistochemistry signal, which is high in healthy tissue, medium in the
infarct penumbra, and low to nonexistent in the infarct core [25,26]. By using multi-label
immunofluorescence of neuroinflammatory cells and MAP2 in rodents, a recent study has been
able to describe the early post-stroke relationship between the infarct core and penumbra with
microglia and astrocytes [27]. In the 2-day re-perfused penumbra, activated astrocytes make a
barrier that surrounds the activated M2 microglia-dense infarct core [27]. At later timepoints,
activated astrocytes can be mostly found in the center of the infarct while M1 activated microglia
tend to be in peripheral regions and remote regions [26–30].
1.3.4 WM Microglial Activation and Disease in Subcortical Stroke
Before describing WM microglial activation, it is necessary to describe the potentially related
measurements of WM integrity. WM integrity can be measured with diffusion tensor imaging
(DTI), as described below, but the measurements can often have more than one biological
interpretation. As one of many magnetic resonance imaging (MRI) techniques, DTI quantifies
the rate and directionality of water diffusion. The rate and directionality are represented in the
parameters mean diffusivity and fractional anisotropy, respectively. Fractional anisotropy (FA)
in particular can be related to WM integrity, with high FA reflecting relatively unimpeded
diffusion parallel to the axonal fibers and restricted diffusion perpendicular to the direction of the
myelinated axonal fibers [31]. Decreased FA and increased mean diffusivity has been related to a
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decrease in myelin content, axon count, and increase in CSF, while the decrease of both FA and
mean diffusivity has been interpreted as gliosis, tract incoherence, and a decrease in axon count
[31]. Although DTI alone cannot specifically measure myelin content or axon count, changes in
FA and mean diffusivity can be interpreted in terms of WM integrity.
Clinical studies of WM disease after subcortical stroke have found that remote regions of
the directly affected tract have increased microglial activation and reduced integrity, and that
remote WM of tracts that were not directly affected have a late reduction in integrity. In particular,
one study showed that remote regions of the directly affected pyramidal tract, which is the major
WM tract related to motor function, had increased microglial activation and decreased WM
integrity, as indicated by FA, throughout the whole tract at <3 weeks and at 6 months post-stroke
[1]. In that study, microglial activation was measured in vivo by using PET to take advantage of
the increased microglial and astrocyte expression of TSPO. As subcortical strokes outside the nonpyramidal tract had no effect on pyramidal tract microglial activation and integrity, it appeared
that the WM tract had to be directly affected by a subcortical stroke for changes in integrity and
microglial activation to be detectable by 6 months after stroke in humans. In contrast, the same
group found late changes in integrity of a WM region that was not directly affected; the
transcallosal motor fiber FA was normal within 20 days but decreased by 6 months after
subcortical stroke in the pyramidal tract and not after subcortical stroke outside the pyramidal tract
[32]. Overall, this data suggests that subcortical stroke in the pyramidal tract leads to early
disintegration of directly connected WM and late disintegration of functionally connected WM.
Whether the functionally connected WM experiences microglial activation and whether these
findings can be generalized to all subcortical strokes in the pyramidal tract is pending further
research.
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Leukoaraiosis, also identified as WM hyperintensities using T2-weighted or fluidattenuated inversion recovery (FLAIR) MRI, is associated with subcortical lacunar stroke, but not
with large subcortical strokes [33]. WM hyperintensities usually refer to leukoaraiosis of presumed
vascular etiology, but WM hyperintensities increase with normal aging and may appear due to a
variety of pathologies [33,34]. For example, WM hyperintensities have been histologically
attributed to various changes such as microglial and astrocyte activation, endothelial activation,
edema, vacuolization, demyelination, axonal loss, and the presence of proteins including
fibrinogen, immunoglobulins, and thrombomodulin [33]. People with a moderate or severe extent
of WM hyperintensity were more likely to have experienced a lacunar stroke than those with mild
WM hyperintensities [35]. On the other hand, large subcortical strokes such as striatocapsular
stroke are less prevalent in people with WM hyperintensity of a moderate or severe extent
compared to mild extent [36].
1.3.5 WM Disease Relationship with Cognition in Subcortical Stroke
There is an established relationship between WM disease and cognition in people with subcortical
stroke. In people with lacunar stroke, there is an increasing relationship between executive
dysfunction and extent of WM hyperintensities [37]. Moreover, another study found that after a
silent lacunar infarct, the reductions in FA in the left external capsule correlated to decreases in
memory and language ability [38]. As for large subcortical stroke, a study showed that after 3
months post-stroke, people with a stroke that had a poorer cognitive outcome had reduced FA in
several WM regions on the contralateral side, while those with a good cognitive outcome only had
reduced FA in the contralateral corpus callosum genu [39]. Overall, this suggests that an increasing
load of WM disease after a subcortical stroke often correlates with cognitive decline.
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1.4 Alzheimer’s Disease (AD)
1.4.1 AD Stages and Diagnosis
AD is a neurodegenerative disease, distinct from subtle cognitive loss associated with aging,
characterized by progressive memory loss and the proteopathies of beta-amyloid (Aβ) and tau.
Although the focus of this thesis is WM microglial activation, it is important to discuss the clinical
pathogenesis of AD to contextualize our transgenic prodromal AD rat model. In terms of
pathogenesis, Aβ deposits and plaques originate from amyloid precursor protein (APP), which is
cleaved into Aβ monomers that eventually aggregate into deposits and [40]. As for tau, the
microtubule-associated protein tau (MAPT) gene produces six splicing isoforms that bind
microtubules and may undergo hyperphosphorylation before aggregating into neurofibrillary
tangles [41]. Overall, Aβ and tau are both important diagnostic hallmarks of AD, but Aβ
pathogenesis appears to start before tau pathogenesis. These proteopathies often precede the onset
of memory loss, mild cognitive impairment, and mild AD, moderate AD, and severe AD [42,43].
Mild cognitive impairment precedes the progressive loss of memory known as dementia, which is
diagnosed based on substantial concern and longitudinal decline in two cognitive domains
including memory according to a mental status exam or neuropsychological testing such as the
widely used clinical dementia rating. In addition to Aβ and tau proteopathies, clinical evidence
also suggests that WM changes can occur early before cognitive impairment [44].
Although the above stages define the severity of AD, the clinical diagnosis of AD depends on the
quality of evidence, which in increasing order can be classified as: possible AD, probable AD, and
proven AD (Fig. 1.1) [45]. To give a diagnosis of proven AD, an antemortem diagnosis of possible
AD or probable AD needs to be supplemented by post-mortem histopathology showing Aβ neuritic
plaques as scored by the Consortium to Establish a Registry for Alzheimer’s disease (CERAD)
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and neurofibrillary tau tangles in the neocortex and hippocampus as staged by Braak [46]. A
diagnosis of AD may also be supported by post-mortem detection of Aβ deposits as scored by Thal
et al. [47]. Overall, knowing these differences in diagnosis may help explain why some clinical
studies differ in their results about the various white matter pathologies.

Fig 1.1 AD diagnosis. Diagnosing a stage of AD is based on severity of symptoms, while nonresearch diagnosis of AD is based on evidence including an AD-like decline of memory (possible
AD), absence of other diseases (probable AD), and the histological presence of amyloid and tau
(proven AD) [45]
1.4.2 WM Microglial Activation and Disease in AD
Before discussing WM microglial activation in AD, it is important to recognize that
neuroinflammation in AD is still a subject of research [48]. In AD, the initial thought was that
neuroinflammation only occurs at the site of amyloid deposition. Evidence suggested that
excessive accumulation of amyloid induced microglial activation for clearance, which if
insufficient led to amyloid deposition and persistent neuroinflammation that had a neurotoxic role
[49–52]. Although that explained why neurotoxic activated M1 microglia and A1 astrocytes could
be found at the neocortex and hippocampus, in which amyloid is usually deposited, it did not
sufficiently explain recent findings that activated M1 microglia can be found in the WM of people
with early-onset AD and rat models of prodromal AD [4,53–55].
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The presence of WM microglial activation changes is controversial in people with lateonset AD, but early-onset AD seems to have elevated WM microglial activation. To differentiate
between early-onset AD and severity of AD, it is important to first discuss Braak staging in detail:
Braak staging is often used to define the severity of neurodegenerative diseases using intensity and
location of tau pathology; a Braak stage I is often localized to the lower brain stem and the earliest
locations where pathology develops while a Braak stage VI has intense tau staining in those early
locations and additionally has pathology in other locations including the neocortex [56]. Earlyonset AD with severe tau pathology indicated by a Braak stage V-VI has been shown to have
elevated WM microglial activation in the transentorhinal cortex and frontal cortex, which
according to Braak stages are some of the earliest and latest regions affected in AD respectively
[4]. people with early-onset AD and early Braak stages were not investigated, this suggests that
WM microglial activation may play a role at least during the late Braak stages of AD pathology.
As for people with late-onset AD, histology studies have shown that WM microglial activation is
similar between people with late-onset AD and controls [4].
On the other hand, TSPO-PET data of people has been controversial; Kreisl et al. showed
normal WM microglial or astrocyte activation in mild cognitive impairment and AD while
Suridjan et al. showed elevated WM microglial activation in AD [57,58]. As only Suridjan et al.
noted the presence of WM hyperintensities and both studies controlled for TSPO genotype and
used structurally similar PET radiotracers, we speculate that an elevated WM microglial or
astrocyte activation may be attributed to the presence of lesions or to a late stage of AD [49]. More
research is needed to determine the stage at which WM microglial activation appears in humans.
Rodent histological studies by our group have implicated WM microglial activation as an
early feature of AD pathology. In particular, we found that a Fischer 344 rat model of prodromal
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AD, which overexpresses human Swedish- and Indiana-mutated amyloid precursor protein
(TgAPP21) to produce high levels of Aβ without depositing amyloid plaques, has elevated WM
microglial activation that is proportional with age, correlates with executive dysfunction, and is
predictive of eventual memory loss [53–55]. Accordingly, WM microglial activation may be
related to other disease findings in WM of people with disintegration, demyelination, WM
hyperintensities, and atrophy [59–61].
WM integrity as measured by DTI MRI is decreased in people with late AD, but the stage
at which disintegration begins remains controversial. By late AD, most evidence supports that WM
integrity has deteriorated [62]. In contrast, the evidence for earlier stages is conflicted. For
example, a 1-year longitudinal and cross-sectional study by Nowrangi et al. showed that the most
commonly used DTI measurement FA was and remained similar between healthy controls and
people with mild cognitive impairment. There was an observed increase in the other DTI
measurement of mean diffusivity, which the authors attributed to loss of neurons, axons, and
dendrites, in people with mild cognitive impairment [61]. On the other hand, a study with a 2-year
follow up by Zhuang et al. found that FA was initially lower in 16 people who were normal
converted to amnestic cognitive impairment compared to 173 people who remained cognitively
normal [44]. To resolve this conflict, a longitudinal study with a larger sample size is necessary
and is expected to be provided by the Alzheimer's Disease Neuroimaging Initiative [63].
WM demyelination has also been detected throughout the course of AD using the myelinsensitive MRI measurement, magnetization transfer ratio (MTR). Magnetization transfer imaging
can use the transfer of magnetization between protons of free water and those bound to
macromolecules to measure MTR, which corresponds to myelin in WM. In one study, reduced
MTR was detected in mild cognitive impairment and AD using a voxel histogram peak analysis,
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but this was not detectable using mean MTR [64]. The limited reduction in MTR might imply that
mild cognitive impairment represents an AD stage at which WM demyelination has not fully
occurred. In late AD, the loss of myelin has been histologically confirmed using Luxol fast blue
staining [65].
1.5 Measuring WM Microglial Activation
Given the importance of WM in neuronal communication and the observation that microglial
activation can have deleterious effects, it is important to study microglial activation in the WM.
Amongst the many molecules that can mark microglial activation, our interests are in the major
histocompatibility complex (MHC) class II molecules and translocator protein (TSPO).
1.5.1 Major Histocompatibility Complex Class II (MHCII) Molecules
MHCII molecules are important in adaptive immunity and often measured to study WM microglial
activation in multiple sclerosis and AD. MHCII molecules are a group of molecules that are
expressed by the MHCII region of the genome in organisms that have them, and include those that
have a structure made up of an alpha chain and beta chain folding together to integrate in lipid
membranes and make an extracellular domain for presenting antigens to other cells. A well studied
example of this is the presentation of antigens to the T-cell receptor on CD4+ T cells, which is a
type of adaptive immunity that could also have cytotoxic effects when activated [66]. In people
with early-onset AD, a recent study has also demonstrated with immunohistochemistry (IHC) that
microglial activation and MHCII molecules are increased in the WM [4]. Given observations of
activated MHCII microglia in the WM of early-onset AD and the potential cytotoxic effects of
MHCII molecules, MHCII molecules are compelling markers of WM microglial activation.

14
1.5.2 Translocator Protein (TSPO)
As mentioned in earlier sections, TSPO-PET has been used to observe chronic WM inflammation
in people with subcortical stroke and people with AD [1,58]. This makes it an ideal candidate for
in vivo imaging of chronic WM MHCII microglial activation.
TSPO was discovered as a variant of the central benzodiazepine receptor that had
differences in ligand binding and was expressed in the kidney, which led to its initial name
peripheral benzodiazepine receptor (PBR) [67]. PBR was renamed to TSPO because of its
implication in the intracellular movement of cholesterol, but some authors have stated that this
lacks sufficient experimental proof [68,69]. Nevertheless, TSPO has been implicated in a variety
of functions and as a marker of neuroinflammation [70].
Neuroinflammatory expression of TSPO has been mostly attributed to activated microglia
and, in some studies, activated astrocytes. Initial studies of rat brains reported that TSPO
expression could be attributed to activated microglia and astrocytes [71,72]. Recent studies have
suggested that TSPO is not expressed by astrocytes [73,74]. Astrocyte expression of TSPO may
be circumstantial as stroke studies of TSPO have shown that the number of astrocytes expressing
TSPO increases with time after a stroke [28,75,76].
1.6 Positron Emission Tomography (PET)
Although MRI can quantify WM integrity, demyelination, hyperintensities, and the core and
penumbra of a stroke, it cannot specifically measure microglial activation. WM microglial
activation can, however, be measured in living subjects using TSPO-PET. In this thesis, the main
objective was to determine whether TSPO-PET can detect WM microglial activation that is
marked by MHCII. Accordingly, the follow sections provide background on PET.
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PET radiotracer production typically begins with a cyclotron that accelerates a positively
charged particle into a target to produce positron-emitting radioisotopes. Positron-emitting
radioisotopes such as 18F and 11C, which have a half-life of 109.7 and 20.4 mins respectively, are
incorporated into exogenous agents with high affinity and specificity for the targeted molecule.
When in the subject, the radiolabeled molecules accumulate at the regions of interest and emit high
energy positrons that annihilate with nearby electrons to produce two antiparallel photons at an
energy of 511 keV. These gamma rays exit the body to the PET scanner, where they are detected
in coincidence and converted into a signal by a ring of scintillator arrays that is optically coupled
to photodetectors.
The acquired signal is stored in list-mode data set (containing detector locations and
detection time for each coincidence event), processed into sinograms, and reconstructed into
volumes portraying the distribution of PET tracer averaged over a period of time in a single frame
or multiple frames. For a 3D acquisition, each frame of data can be binned into a set of N2 oblique
sinograms between detector rings, where N is the number of detector rings and a sinogram is a
graph that plots the number of coincidences detected for each possible detector pair [77].
Sinograms are corrected for random and scatter emission events before PET images are
reconstructed using a filtered back projection reconstruction or iteratively by comparing them to
the sinograms of different theoretical volumes. For example, the iterative reconstruction algorithm
used in chapter 2, 3D ordered-subset expectation maximization followed by fast maximum a
posteriori (OSEM3D/FMAP), works by dividing the measured sinograms into non-overlapping
subsets and using only one subset at a time to minimize the difference between the measured subset
and a theoretical subset that is based on the forward projection of a model image (OSEM3D), and
then by maximizing a function that penalizes images that do not fit the data well (MAP) [78,79].
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1.6.1 PET Spatial Resolution
As producing a PET volume requires information about detector location, detector size is inversely
related to resolution, but it is also directly related to sensitivity. In other words, decreasing detector
sizes could increase resolution by providing a better estimate of where gamma rays strike the PET
instrument, but sensitivity would decrease as the detectors might become too small to detect a
sufficient number of photons.
System resolution is also limited by positron physics. For one, before annihilating with
electrons to produce two 511 keV gamma rays, positrons can diffuse for a distance related to their
maximum emission energy. The uncertainty about where the positrons were emitted poses a
resolution limit. Second, resolution is limited because the produced gamma rays are not perfectly
anti-parallel if the positron has residual momentum, which results in an angle that ranges from
179.75° and 180.25°, which means that there is a range for where the annihilation could have
happened. To reduce the range, the diameter of the bore could be decreased, but this is only feasible
up to a limit. Overall, the resolution of any PET system is physically limited by the distance a
positron could diffuse before annihilating and the fact that the produced gamma rays are not always
perfectly anti-parallel.
1.6.2 Radiotracer Target, Sensitivity, and Specificity
Radiotracers may be divided based on their target reaction and kinetic behavior. Target reactions
guide the initial process of radiotracer development; for the development of radiotracer to be
worthwhile, it has to have clinically meaningful implications. Example reactions include
physiological processes such as perfusion or blood-tissue exchange, but the majority of PET
tracers developed target a protein [80]. Based on their kinetic behavior, radiotracers may be further
divided into those that are reversible and irreversible [81]. Reversible radiotracers are able to
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achieve equilibrium by the end of an experiment while irreversible radiotracers generally do not
achieve equilibrium. An example of an irreversible radiotracer is [11C]deprenyl, which binds by
making a covalent bond with its target protein monoamine-oxidase B to estimate CNS amine
breakdown such as that of dopamine [82]. Although an irreversible radiotracer is generally thought
to be advantageous because it simplifies analysis, it can be disadvantageous by having limited
sensitivity in regions of high target concentrations when there are insufficient amounts of
radiotracer to saturate the targets [82].
Sensitivity of PET radiotracers refers to their affinity to the target reaction, such as binding
for neuroreceptor radiotracers and delivery for flow radiotracers, and can be validated in vitro, ex
vivo, and in vivo. Affinity to the target reaction is a practical concept for quantifying how
effectively the radiotracer could detect the target reaction. For reversibly binding tracers, in vitro
samples containing the target are usually subject to competitive binding assays as part of the initial
validation of a radiotracer [83]. Later studies may validate in vivo binding affinity by injecting a
cold competitive binder in experiments of blocking or displacement, but this is not feasible for all
target reactions. For example, blocking or displacement studies are not feasible for TSPO because
an unsafe concentration of cold binding molecules is required to saturate the many TSPO binding
sites in the body [84].
PET radiotracer specificity is one of the most prevalent reasons for why radiotracers fail,
and although there are in vitro approaches to quantify specificity, they do not always correspond
to in vivo results. Radiotracers often fail in vivo because they bind to off-target proteins or lipids,
which could have misleading consequences. Ideally, in vitro tests would have been conducted to
evaluate radiotracer specificity. For brain studies, a high lipophilicity of the radiotracer often
corresponds to high nonspecific binding [83]. Nevertheless, radiotracers could have low
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lipophilicity and still demonstrate nonspecific binding in vivo; in these cases, competitive binding
experiments that can quantify sensitivity show a high PET signal after injection of the competitive
molecule.
1.6.3 Tracer Kinetic Modelling
Tracer kinetic modelling has the practical purpose of condensing dynamic information into
quantities of the primary processes that affect tracer distribution. PET experiments can produce a
lot of dynamic information because, after being injected into a subject, tracers do not
instantaneously get distributed according to the quantity of the target reaction. Instead, the tracer
dynamically experiences two or more processes including delivery, clearance, and the target
reaction. As a result, the tracer undergoes dynamic change, and this can be seen by plotting the
tracer radioactivity against time to construct what is frequently referred to as a time-activity-curve.
Although for an ideal radiotracer, an estimate of the target reaction may be semi-quantified using
a single late timepoint activity measurement such as standardized uptake value (SUV) normalized
to the injected dose and subject weight or the later-discussed reference region-based uptake ratio
(UR - often called SUVR), it is possible to use tracer kinetic modelling to obtain an exact rate
measurement of the target reaction, delivery, clearance and other reactions or processes. By
condensing a lot of information into exact rate measurements, tracer kinetic modelling serves a
practical purpose.
The types of rates and their interpretation depend on the chosen tracer kinetic model.
Although more complicated models can be more informative, they are computationally demanding
to solve and, more importantly, often less robust.
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1.6.3.1 Compartmental Modelling
Compartmental models are well-suited to maximize the current abilities of PET. Compartmental
tracer kinetic models are based on how the rate of reactions are linearly related to their rate constant
and substrate concentration, which may be considered uniform using conceptual compartments
such as states, locations, or their combination. In reality, there are many theoretical tracer
compartments, but the ability to resolve them are limited by current insufficiencies in PET
including signal, resolution, and the inability to distinguish radioactivity sources [85]. Instead,
these PET insufficiencies and the ability to make uniformity assumptions dictate whether a
compartment is resolvable. In doing so, compartmental models maximize the number of practical
parameters that can be accurately extracted from PET data.
The 2TCM provides the highest number of parameters that are usually solved for in PET
studies. It is based on the distinction of two tissue compartments: a nondisplaceable compartment
(C1) that is in equilibrium with the bound compartment (C2), with a tracer-dependent distinction
between a plasma compartment (Cp) and a blood compartment (Cb). Having been designed for
tracers with slow reversible reactions, the 2TCM has 5 microparameters: K1 = plasma-tonondisplaceable-compartment transfer rate (delivery), k2 = nondisplaceable-compartment-toplasma transfer rate (clearance), k3 = nondisplaceable-compartment-to-target-compartment
transfer rate, k4 = target-compartment-to-nondisplaceable-compartment transfer rate, and Vb =
blood volume fraction (Fig. 1.2) [86]. Each of these parameters has an important clinical relevance.
Namely, K1 equates to the product of blood flow and tracer extraction fraction, the latter of which
is related to permeability of the BBB in PET studies of the brain. Both of these measurements
could be affected by a pathology. On the other hand, k2 is related to K1; if blood flow changes K1,
k2 rapidly compensates for the change [87,88]. Vb is relatively straightforward; a pathology could
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change the blood-volume fraction. Lastly, k3 and k4 correspond to the in vivo- and tracer-dependent
rate estimates of association with the available target protein and its reversal, respectively. As these
two rate estimates are related to the amount of the target molecule, which should have a clinically
significant interpretation, the 2TCM is usually used when possible.
An important requirement of the 2TCM is that it requires invasive blood sampling and
metabolite fractionation to determine the fraction of non-metabolized radiotracer in the plasma
(Cp) and the blood compartment (Cb). This is because radiotracers can be metabolized and the
metabolites cannot be differentiated from the parent by the PET detector. To model only the parent,
its fraction in the arterial blood is required. Given the invasive nature of arterial sampling, noninvasive methods to derive the input function are actively being pursued [89,90].

Fig 1.2 A visual representation of a 2TCM. In this model, the plasma pool (Cp) is distinguished
from the whole blood pool (Cb). When the whole blood pool is multiplied by the volume fraction
of tissue that is occupied by blood vessels (Vb), the blood-sourced activity (Vb x Cb) can be
separated from the rest of the tissue (C1 and C2), which all together makes up the detector-measured
CT as defined in Eq 1.3. The radiotracer gets exchanged and eventually achieves equilibrium
between Cp and C1, and between C1 and C2. The rates at which the parent radiotracer is exchanged
between compartments are indicated using K1 (delivery), k2 (clearance), k3 (binding), and k4
(unbinding)
Compartmental models are often solved using the nonlinear least-squares approach, but
this can produce inaccurate microparameters [91,92]. The approach continually alters parameters
of a simulated curve until it matches the measured curve as guided by numerical curve differences
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and, usually, derivative-based algorithms. Unfortunately, derivative-based algorithms require an
accurate initial estimate to converge to the global optimum as there can be more than one local
optimum, which is the result of noise and inversely correlated model parameters [91,93]. As
nonlinear least-squares algorithms are more likely to find the global optimum if the parameter
search space is smaller, most studies eliminate one dimension by fixing Vb to a predetermined
value. Another way to reduce the number of dimensions can be used for the 2TCM; blocking or
displacement experiments may be used to simulate a scenario where are k3 and k4 equal to zero,
but as mentioned earlier, these are not feasible for all PET targets. On the other hand, the
parameters may also be reduced by setting k3 and k4 to zero, which is valid if the tracer kinetics
may effectively be modeled with a single tissue compartment model (1TCM) when the tracer does
not have a target reaction beyond delivery or if the target reaction rapidly achieves equilibrium
[94]. Overall, the inability to estimate the initial target parameters and the local minimum problem
make it challenging for the nonlinear least-squares-fitting approach to prove that the converged
parameters are the true parameters [95].
1.6.3.2 Total Distribution Volume (VT)
Regardless of method, most PET papers that use tracer kinetic modelling on reversible binding
ligands report the robust but aggregated macroparameter VT. VT is defined as the equilibrium ratio
of radiotracer concentration in the region of interest, not including the blood component, to that in
plasma (Eqs. 1.1 and 1.2). A downside to this definition is that VT largely consists of the
equilibrium concentration in the non-displaceable compartment, making VT an aggregated
macroparameter that is not purely representative of the target binding reaction. On the other hand,
this activity-ratio-based definition allows for robust calculation of VT; VT will be accurate if the
measured curve reasonably matches the fitted curve, which can be done using the 1TCM or 2TCM
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(equations below). Overall, despite VT being an aggregated macroparameter that contains
information about the non-displaceable compartment, its activity-ratio definition makes it a robust
parameter to report.
Eq 1.1 (1TCM):

Eq 1.2 (2TCM):

𝑉𝑇 =

𝑉𝑇 =

𝐾1
𝑘2

𝐾1
𝑘2

(1 +

𝑘3
𝑘4

)

1.5.3.3 Logan Graphical Analysis
Logan graphical analysis is one of the most widely used methods for determining VT of reversibly
binding tracers. It started in 1990, when Patlak’s work on graphical analysis of non-reversible
tracers inspired Logan to extend the work to reversible tracers [96]. At the time, Logan graphical
analysis provided a method to solve VT that was computationally simple, robust, and does not
require the specification of a compartmental model; although based on compartment models,
differentiating between them does not change the slope on the graphical analysis and therefore
distribution volume. Improvements in PET signal-to-noise ratio have increased the robustness of
Logan graphical analysis by correcting earlier underestimates of VT [97]. Given this improvement
in signal-to-noise ratio, the simplicity, and model-independence of Logan graphical analysis, it is
no surprise that Logan graphical analysis is still one of the most widely used methods for
calculating VT.
Logan graphical analysis follows the simple linear regression equation Y = slope•X +
intercept. Although Logan analysis is model-independent, the interpretation of the slope and
intercept depends on the model and assumptions. For a 2TCM that distinguishes between the
concentration of radioactivity in total blood and the concentration of free parent metabolite in the
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plasma, a full solution is provided in Appendix A. Briefly, the model, assumptions, and solution
are as follows:
𝐶𝑇 (𝑡) = 𝐶1 (𝑡) + 𝐶2 (𝑡) + 𝑉𝑏 𝐶 𝐵 (𝑡)

Eq 1.3:
𝑑𝐶1 (𝑡)

Eq 1.4:

𝑑𝑡

= 𝐾1 𝐶𝑝 (𝑡) − 𝑘2 𝐶1 (𝑡) − 𝑘3 𝐶1 (𝑡) + 𝑘4 𝐶2 (𝑡)
𝑑𝐶2 (𝑡)

Eq 1.5:

𝑑𝑡
𝑡

∫0 𝐶𝑇 (𝑢)𝑑𝑢

Eq 1.6:

𝐶𝑇 (𝑡)

= 𝑘3 𝐶1 (𝑡) − 𝑘4 𝐶2 (𝑡)

𝑡

= 𝑉𝑇

∫0 𝐶𝑝 (𝑢)𝑑𝑢
𝐶𝑇 (𝑡)

−

1
𝑘
1
(1 + 𝑘3 ) + 𝑉𝑏 (1 + 𝑘
𝑘2
4
2

𝑡

+

𝑘3 ∫0 𝐶𝐵 (𝑢)𝑑𝑢
) 𝐶 (𝑡)
𝑘4 𝑘2
𝑇

Where for reversible tracer binding in a 2TCM:
𝑉𝑇 =

𝐾1
𝑘2

(1 +

𝑘3
𝑘4

)

𝐶𝑇 = Concentration of total radioactivity in the tissue
𝐶𝑝 = Concentration of free parent metabolite in the plasma
𝐶𝐵 = Concentration of total radioactivity in whole blood
𝐶1 = Concentration of parent metabolite in the non-displaceable compartment
𝐶2 = Concentration of parent metabolite in the bound compartment
𝑉𝑏 = The ROI volume fraction of vascular tissue
𝐾1 = plasma-to-unbound-compartment transfer rate (delivery)
𝑘2 = unbound-compartment-to-plasma transfer rate (clearance)
𝑘3 = unbound-compartment-to-bound-compartment transfer rate (binding)
𝑘4 = bound-compartment-to-unbound-compartment transfer rate (unbinding)

1

− (𝑘 )
4

𝐶2 (𝑡)
𝐶𝑇 (𝑡)
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1.6.4 Reference Regions
In PET studies, reference regions techniques make quantification convenient because they omit
the need for invasive blood sampling and microparameter fitting. Blood sampling can be avoided
when using reference regions techniques because they omit the need for concentration of free
parent metabolite in the plasma, the obtaining of which (i) is invasive because it requires
catheterization for blood samples and (ii) labor-intensive and error-prone because it requires
methods for extracting metabolite fractions from blood samples. An example of such a technique
is the semi-quantitative uptake ratio approach (UR), which relies on the assumption that there are
no unmetabolized radioligands in the reference region. Additionally, to determine the important
ratio of radiotracer concentration in the specifically bound compartment to that in the
nondisplaceable compartment (BPND), error-prone microparameter fitting can be avoided by using
reference regions and the Logan VT-based reference region techniques (equation below). This
requires the assumption that the reference region is physiologically identical to the region of
interest except for the target reaction(s) being quantified, which in the reference region should be
nonexistent. Therefore, given the right assumptions, reference region techniques are convenient
because they allow the determination of BPND without error-prone microparameter fitting and, also
for determining the semi-quantitative UR, without blood sampling and metabolite analysis.
Eq. 1.7:

𝑉 (𝑅𝑂𝐼)

𝐵𝑃𝑁𝐷 (𝑅𝑂𝐼) = 𝑉 𝑆

𝑁𝐷 (𝑅𝑂𝐼)

=

𝑉𝑇 (𝑅𝑂𝐼)− 𝑉𝑁𝐷 (𝑅𝑂𝐼)
𝑉𝑁𝐷 (𝑅𝑂𝐼)

=

𝑉𝑇 (𝑅𝑂𝐼)− 𝑉𝑇 (𝑅𝑒𝑓)
𝑉𝑇 (𝑅𝑒𝑓)

=

𝑘3
𝑘4

Where Vs is the distribution volume in the bound compartment and VND is the distribution
volume in the nondisplaceable compartment
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1.6.5 Ex Vivo PET Validation
Quantitative validations of PET are usually done using the ex vivo methods of autoradiography
and western blotting. Relative to PET, autoradiography allows validation of the PET radiotracer
at a higher resolution and, importantly, simpler binding context. The higher resolution is derived
by placing tissue sections incubated with radiotracer closer to high-resolution detectors than
possible with PET. Analysis of binding is simplified because (i) the radiotracer does not need to
pass a blood compartment, (ii) equilibrium can be achieved rapidly, and (iii) the non-specific
binding can be assessed using non-radioactive ligands at toxic concentrations [98]. In contrast,
western blotting resolution is technically limited, but it can produce pure quantitative
measurements of the target protein amount. The user must sample a region of interest, homogenize
it, separate it in a gel, incubate it with a target-protein-binding chromogenic antibody complex,
then use the amount of signal it emits to quantify protein amount by regression from predetermined
quantities of standard proteins [99]. Overall, autoradiography provides high resolution of
radiotracer binding while western blotting provides accurate quantities of the target protein without
the need to quantify binding constants.
1.6.5.1 Immunohistochemistry (IHC)
IHC provides a very high resolution of the target protein, but the measurements are semiquantitative. Briefly, IHC is when tissue sections are incubated with a chromogenic antibody
complex that can be imaged with high-resolution microscopes. IHC resolution is much higher than
PET because (i) the chromogen is near the target protein and (ii) the physical laws that limit
microscopy are much less restrictive. Unfortunately, traditional IHC is semi-quantitative and
restricted to counting or area coverage analysis because the protein-to-signal relationship is not
perfectly proportional. This is mainly because the binding between protein antigen and antibodies
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is not stoichiometric but can also be attributed to chromogens that do not follow Beer-Lambert’s
law. All together, although IHC is semi-quantitative, the process and physical laws give it a much
higher resolution than PET.
1.6.6 TSPO-PET
Given the ability of TSPO to mark activated microglia that was mentioned in section 1.5.2, and
the knowledge of ligands that can bind TSPO, many TSPO-targeting radiotracers have been
developed to quantify microglial activation in vivo [100]. Initial radiotracers included those based
on benzodiazepines such as [11C]Ro5-4864 and isoquinoline carboxamides such as [11C]PK11195.
In a later generation, [11C]Ro5-4864 binding inspired the development of [11C]DAA1106 and other
phenoxy acetamides with high binding affinity such as [11C]PBR28 and [18F]FEPPA. New
radiotracers for TSPO continue to be developed because of quantification issues.
TSPO-PET quantification has been hindered by low binding specificity in the initial
radiotracer [11C]PK11195, sensitivity to human polymorphisms in newer generation tracers, and
the absence of a true reference region. The first PET tracer was [11C]PK11195, but its low binding
specificity limited the signal-to-noise ratio of true TSPO expression [101]. Binding specificity was
improved in newer generation PET tracers, but they proved sensitive to TSPO human
polymorphisms and therefore additionally required a genetic analysis for accurate quantification
[102]. This polymorphism sensitivity initially seemed solved by [18F]GE180 and the yet newer
radiotracer [11C]ER176, but these were later revealed to be artifacts or did not translate from in
vitro studies to in vivo studies respectively [103,104]. Finally, the absence of a true reference
region that is devoid of TSPO expression has made it technically challenging to quantify PET
tracer uptake [105].

27
1.7 Rationale and Objectives
AD and subcortical stroke are both common neurological diseases with unfortunate cognitive
prognoses. Although their main pathologies are different, WM microglial activation and other WM
abnormalities are key components to the pathogenesis of both AD and stroke. Specifically, our
group has used preclinical co-morbid rodent models of disease to demonstrate that diffuse WM
microglial activation increases with normal age, is accelerated in transgenic AD rats and following
subcortical stroke, associates with executive dysfunction, and is predictive of learning and memory
impairment [29,30,53,55,106].
To longitudinally measure cognitive function and WM microglial activation , there is a need
for an in vivo imaging modality that can image WM microglial activation. As TSPO-PET can
quantify microglial activation and has been used to observe chronic WM inflammation in
subcortical stroke and AD, we hypothesized that the chronic WM microglial activation that is
histochemically detected using MHCII in our subcortical stroke and prodromal AD rat models can
also be detected using TSPO-PET. To test this hypothesis, this thesis had the following objectives:
1. To investigate WM microglial activation in a rat model of prodromal AD with TSPO-PET
using the 2nd generation radiotracer, [18F]FEPPA.
2. To investigate WM microglial activation longitudinally in a rat model of subcortical stroke
with TSPO-PET.
3. To investigate and validate WM TSPO expression in a rat model of subcortical stroke at 7days and 28-days using IHC.
4. To investigate WM microglial and astrocyte activation in a rat model of subcortical stroke
using MHCII, iNOS, and GFAP IHC at 7-days and 28-days post-stroke.
5. To compare TSPO-PET and TSPO IHC to MHCII IHC.
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Results from these studies are reported in Chapter 2, which is currently under review for
publication in the journal European Journal of Nuclear Medicine and Molecular Imaging
(EJNMMI) Research.
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Chapter 2: TSPO PET Detects Acute Neuroinflammation but not Diffuse Chronically Activated
MHCII Microglia in the Rat
The figure numbers were modified to fit in this thesis. Additional changes were made to this
manuscript since being submitted for publication.
2.1 Introduction
Diffuse inflammation of brain white matter (WM) has been clinically implicated in the pathology
of brain diseases including schizophrenia, traumatic brain injury, and Alzheimer’s Disease [1–3].
In the continuum from mild cognitive impairment to Alzheimer’s disease (AD), diffuse WM
inflammation may explain why WM undergoes demyelination, tract disintegration, and atrophy
while patients undergo cognitive decline [4–6]. To measure WM inflammation in living subjects,
previous studies have used PET tracers that target the 18 kDa translocator protein (TSPO) [7,8].
TSPO is overexpressed in astrocytes and microglia during their activation, but the subtypes of
activated microglia that express TSPO remains a subject of research.
Microglia that express major histocompatibility complex class II (MHCII) molecules,
which are involved in antigen presentation, are considered to be proinflammatory [9]. MHCII
molecules are correlated to cognitive dysfunction throughout AD and diffusely overexpressed in
the WM microglia of patients with early-onset AD [1,10]. Previously, our group correlated diffuse
MHCII activated microglia in WM with cognitive dysfunction in a prodromal transgenic rat model
of AD that overexpresses human Swedish- and Indiana-mutated amyloid precursor protein
(TgAPP21) to produce high levels of Aβ without depositing amyloid plaques [11–13]. We further
demonstrated the importance of diffuse MHCII activated microglia by detecting them in WM
remote to an ischemic subcortical stroke in an endothelin-1 (ET1) rat model that also exhibits
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executive dysfunction [14,15]. Overall, these observations motivate the need to detect MHCII
activated microglia in vivo.
In this study, we used the TgAPP21 and ET1-induced subcortical stroke rat models to
investigate whether TSPO can detect diffuse MHCII activated microglia in WM. To quantify
TSPO in vivo, we used a second-generation TSPO PET tracer ([18F]FEPPA) and validated the
cerebellum

as

a

pseudoreference

region

[16].

TSPO-PET

was

validated

using

immunohistochemistry of TSPO, which was compared to the activated astrocyte marker GFAP
and activated microglia markers iNOS and OX6 (MHCII) in ET1 rats.
2.2 Methods
2.2.1 Animals and Experimental Design
Animal ethics and procedures of this study are in compliance with the Canadian Council for
Animal Care and Western University Animal Care Committee (Protocol 2014-016). Rats were
housed under a 12h/12h light/dark cycle and received access to food and water ad libitum.
This study used male Fischer 344 rats aged 11-14 months. TgAPP21 (n = 11) and wildtype (n = 12) rats were randomly selected to investigate [18F]FEPPA uptake in WM of prodromal
AD. Genotype was validated with PCR as previously described [13].
To study ischemic subcortical stroke, the same wild-type rats that received baseline in vivo
imaging were randomly assigned to a stereotactic injection of 60 pmol endothelin-1 (ET1)
dissolved in 3 μL sterile saline (n = 5) or sterile saline alone for control (n = 6) in the right dorsal
striatum as previously described [17]. Rats were imaged in vivo post-stroke at day 7 and day 28,
at which point they were euthanized for immunohistochemistry. A saline rat was omitted at day 7
because of a tail vein issue and 2 saline rats had to be replaced after baseline because they died.
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An additional group of rats (n = 5 ET1, n = 6 saline) was euthanized at day 7 for acute
immunohistochemistry.
2.2.2 In Vivo Imaging
Each in vivo imaging session consisted of a PET scan followed by MRI and CT. Before PET,
anesthesia was administered at 2 L/min oxygen with 5% isoflurane for induction then maintained
at 2% until after CT. Respiratory rate, heart rate, and body temperature were monitored and
maintained throughout.
2.2.2.1 MRI
MRI was performed on a 3T MRI (Siemens Biograph mMR) with a dedicated quadrature rat brain
coil (Cubresa, 44 mm inner diameter). 2D sagittal and axial T2-weighted fast spin echo (FSE)
images were acquired spanning the brain with an in-plane field-of-view (FOV) = (70 x 70) mm2,
matrix size = 320 x 320, in-plane resolution = (0.22 x 0.22) mm2 and slice thickness = 1 mm. Other
relevant parameters for the FSE sequence include: repetition time (TR) = 2930 ms (sagittal
acquisition) and 3900 ms (axial acquisition), effective echo time = 97 ms, refocusing flip angle =
150°, echo train length = 11, bandwidth = 225 Hz/pixel, and averages = 4.
2.2.2.2 CT
For attenuation correction of the PET, full-body helical CT scans were acquired with a resolution
of (0.20 x 0.20 x 1.25) mm3, tube current = 80 mA, tube voltage = 80 kVp, and rotation time = 1
s (GE Revolution CT). CT images were segmented using Hounsfield-unit thresholds into tissue
and material types with known linear attenuation coefficients at 511 keV.
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2.2.2.3 PET Acquisition and Processing
PET data was acquired dynamically over 90 minutes (Siemens Inveon). Thirty seconds after
initiating the scan, 33.7 ± 5.6 MBq [18F]FEPPA was injected through a tail vein catheter. On day
28, rat tail arteries were cannulated for blood sampling (n = 4). A blood volume of 50 µL was
sampled into tubes with ethylenediaminetetraacetic acid at 2, 8, 16, 64, and 90 minutes postinjection. Blood was centrifuged to extract 15 uL of plasma, which was then loaded onto
omniphilic cartridges (Oasis HLB, Waters). Fractions were eluted with 0%, 20%, and 40%
acetonitrile in 1 mL of solution to elute successively more lipophilic metabolites [18]. Elutants,
blood, and plasma were counted using a calibrated gamma detector.
Decay-corrected PET data from 70-90 minutes post-injection was used for standardized
uptake value (SUV) analysis and dynamic frames of 1 x 27 s, 21 x 3 s, 12 x 10 s, 5 x 30 s, 4 x 60
s, and 16 x 300 s for pharmacokinetic modeling. Appendix B contains time-activity curve
examples of the initial phase and full phase for the input function and critical regions as outlined
in Fig. 2.1: infarct region, contralateral to the infarct region, ipsilateral corpus callosum, and
contralateral corpus callosum. PET reconstruction consisted of 2 iterations of 3D ordered-subset
expectation maximization followed by 18 iterations of fast maximum a posteriori
(OSEM3D/FMAP) with a co-registered CT-based attenuation correction map.
2.2.2.4 PET Analysis
Co-registration, region of interest (ROI) segmentation, and data extraction were performed using
3D Slicer 4.10 [19]. Images were zero-interpolated to an isotropic 0.22 mm voxel size and linearly
co-registered to define the ROI in each rat (Fig. 2.1). ROIs included the T2w-hyperintense infarct
region and contralateral to the infarct region for a positive control, periaqueductal gray,
cerebellum, frontal cortex, WM forceps minor, corpus callosum proximal to the infarct, and corpus
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callosum remote to the infarct. A 4 mm3 spherical ROI was placed in the centre of the cardiac left
ventricular cavity to derive input functions. Input functions were corrected using biexponential
and Hill function population fits of whole blood-to-plasma ratio and unmetabolized [18F]FEPPAto-all metabolites ratio (MATLAB 2019a). Corrected input functions and time-activity curves
were used with an assumed blood volume of 5% to solve for the Logan total distribution volume
(DV – also known as VT) and ratio (DVR) using custom MATLAB scripts. Standardized uptake
value (SUV) was calculated based on weight and injected dose then used to calculate uptake ratios
normalized to the cerebellum (UR).
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Fig 2.1 Analytical Methods. a Representative ROIs delineated on T2w MRI and applied to fused
[18F]FEPPA PET in a control rat at day 7. ROIs are proximal to the rat nose. b Infarct at baseline
and post-stroke day 7 and 28 on T2w MRI. c, contralateral; CC, corpus callosum; CIR, contralateral
to the infarct region, FM: Forceps Minor; i, ipsilateral; IR, infarct region; p, posterior
2.2.3 Immunohistochemistry
All rats were euthanized with an intraperitoneal injection of pentobarbital (Euthanyl, Bimeda MTC
Animal Health Inc) then underwent transcardiac perfusion using 10 mM phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde (PFA). Brains were extracted, fixed in 4% PFA for 24h,
then stored at 4°C in 30% sucrose until they were cryosectioned into 30 µm thick sections
(CryoStar NX50, Thermo Fisher Scientific). Sections were stored in cryoprotectant at -20 °C until
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all tissue was available for 3,3′-Diaminobenzidine immunohistochemistry with avidin-biotin
complex amplification (ABC Staining Kit, Thermo Fisher Scientific). Primary antibodies were
anti-TSPO (1:1000, ab154878, abcam) for TSPO+ cells, anti-iNOS (1:1000, ab15323, abcam) for
proinflammatory microglia, anti-OX6 (1:1000, #554926, BD Pharmingen) for MHCII, and antiGFAP (1:2000, #G3893, Sigma-Aldrich) for activated astrocytes. We used anti-OX6 because it
targets the rat MHCII gamma chain, which is necessary for the proper function of all MHCII
molecules. GFAP is often used as a marker of activated astrocytes because they need it for reactive
astrogliosis and scar formation.
The observer was blinded to experimental group during analysis. Images were acquired
using a Nikon Eclipse Ni-E microscope and Nikon DS Qi2 colour camera on the NIS Elements
Imaging software at a consistent lamp voltage and exposure for each antibody. TSPO cells were
counted using four 20x sections at opposite borders of each defined in vivo region except the
posterior corpus callosum, which used eight. Weak or diffuse staining was considered negative.
GFAP, iNOS, and OX6 within-region % area coverage analysis used large images stitched from
10x magnification fields. Regions were manually defined using the polygon tool to replicate in
vivo delineations of the proximal corpus callosum and forceps minor. The infarct and contralateral
regions were also defined for iNOS. Images were binarized with a consistent threshold to get %
area coverage within each region (ImageJ 1.52a) [12].
2.2.4 Statistical Analysis
All analyses of variance (ANOVA) were based on type III sum of squares (SPSS 26). To start, a
two- or three-way ANOVA (depending on whether time was a variable) was conducted on PET
(between ET1, within region and time) and immunohistochemistry (between ET1 and time, within
region). Unless stated, higher-order interactions had to meet significance before analyzing simpler
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effects with lower-order ANOVA and pooled variances if appropriate. Within-subject sphericities
were accounted for using Greenhouse-Geisser corrections. Posthoc analyses for repeated timepoint
effects were evaluated using Tukey’s honestly significant differences (HSD) unless Shapiro-Wilk
normality or Levene’s variance assumptions were violated, in which case the Wilcoxon signedrank or Mann-Whittney U test were used, depending on whether samples were paired. Correlation
and graphing were performed on GraphPad Prism 7. All data is expressed as mean ± standard
deviation (SD). Significance was set at alpha = 0.05.
2.3 Results
2.3.1 The Cerebellum is an Appropriate Pseudoreference Region for [18F]FEPPA PET
To determine an appropriate pseudoreference region for quantifying [18F]FEPPA uptake,
[18F]FEPPA PET 70-90 min SUVs of the cerebellum and periaqueductal gray were compared
(Figs. 2.2 and 2.3). The region contralateral to the infarct was also compared in the ET1
investigation. SUV was not significantly affected by genotype, ET1, or interaction between ET1
and timepoints (P = ns for two-way and three-way ANOVA). Interestingly, region was a
significant factor in both analyses of TgAPP21 vs. wild-type rats (A.U.: periaqueductal gray =
0.43 ± 0.14; cerebellum = 0.56 ± 0.18; F(1,21) = 53.30, P < 0.0005, two-way ANOVA) and ET1
vs. saline rats (A.U.: periaqueductal gray = 0.43 ± 0.12; region contralateral to the infarct = 0.49
± 0.19; cerebellum = 0.60 ± 0.15; F(2,12) = 27.47, P = 0.001, three-way ANOVA). TSPO
immunohistochemistry cell count of the day 28 infarct site also correlated better with the UR
calculated using the cerebellum (R2 = 0.63, P = 0.0191) instead of the region contralateral to the
infarct (R2 = 0.47, P = ns) or periaqueductal gray (R2 = 0.36, P = ns) (Fig. 2.5). Accordingly,
cerebellum-based [18F]FEPPA UR are reported hereafter.
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Fig 2.2 SUV was significantly different between the pseudoreference regions, cerebellum and
PAG, in wild-type and TgAPP21 [F(1,21)=53.30, P<.0005, two-way ANOVA]. Whole brain SUV
is also shown. CIR: contralateral to the infarct region. PAG: periaqueductal gray. Error = SD

Fig 2.3 Wild-type saline and ET1 rat pseudoreference regions at baseline, day 7, and day 28 after
an injection in the right dorsal striatum. (A) SUV maps overlaid on T2-weighted MRI. (B) SUV
showed a significant effect of region [F(1,21)=53.30, P<.0005, three-way ANOVA]. CIR,
contralateral to the infarct region; PAG, periaqueductal gray. Error = SD
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Fig 2.4 Correlations of distribution volume with distribution volume ratio to candidate
pseudoreference regions. Each point represents one region in one Wt rat at the 28-day post-stroke
timepoint. The coefficients of determination were derived within each rat, averaged, and are
provided in the graph. CIR, contralateral to the infarct region; PAG, periaqueductal gray

Fig 2.5 Correlations of infarct TSPO immunohistochemistry to uptake ratios calculated using
candidate pseudoreference regions. Regression coefficients are provided in the graph. CIR,
contralateral to the infarct region; PAG, periaqueductal gray; IR, Infarct region
2.3.2 [18F]FEPPA UR was not Elevated in WM of TgAPP21 Rats
UR in TgAPP21 and wild-type rats were analyzed to investigate [18F]FEPPA uptake in WM
regions in which our group previously demonstrated MHCII microglial activation [12,13].
Genotype did not have a significant effect (P = ns, two-way ANOVA, Fig. 2.6). This suggested
that [18F]FEPPA PET was not detecting the WM MHCII microglia that were previously reported
in TgAPP21 rats.
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Fig 2.6 Transgenic amyloid precursor protein rats did not have an elevated [18F]FEPPA PET WM
uptake ratio, to the cerebellum, relative to wild-type saline rats. Genotype effect was not significant
(P = ns, two-way ANOVA). CC, corpus callosum; FC, frontal cortex; FM, Forceps Minor; p,
posterior. Error = SD
2.3.3 [18F]FEPPA UR was not Elevated in Remote WM Following ET1-induced Stroke
UR at baseline, day 7, and day 28 after injection of ET1 or saline were analyzed to investigate
[18F]FEPPA uptake in WM with the infarct as a positive control (Fig. 2.7). An interaction between
region, timepoint, and ET1 suggested that UR was increased following ET1-induced stroke only
in regions near the infarct [F(20,120) = 3.66, P = 0.036, three-way ANOVA]. In the infarct ROI
of the ET1 group, UR significantly increased from baseline (0.94 ± 0.16) to day 7 (2.10 ± 0.78; P
= 0.043, Wilcoxon signed-rank) and day 28 (1.77 ± 0.35; P = 0.043, Wilcoxon signed-rank).
Similarly, proximal WM (ipsilateral corpus callosum) UR of the ET1 group significantly increased
from baseline (0.94 ± 0.12) to day 7 (1.42 ± 0.34; P < 0.005, Tukey’s HSD) and day 28 (1.38 ±
0.14; P < 0.005, Tukey’s HSD). UR was not significantly affected in remote WM.
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Fig 2.7 [18F]FEPPA UR was not elevated in remote WM following ET1-induced stroke. a Maps
and b values of longitudinal [18F]FEPPA PET uptake ratio, relative to the cerebellum, revealed a
significant region-ET1-timepoint interaction in saline and ET1 rats [F(20,120) = 3.66, P = .036,
three-way ANOVA]. c, contralateral; CC, corpus callosum; CIR, contralateral to the infarct region;
FM, Forceps Minor; i, ipsilateral; IR. infarct region; p, posterior. Error = SD
2.3.4 TSPO was not Expressed in Remote WM Following ET1-induced Stroke
TSPO immunohistochemistry-based cell counting was performed to confirm [18F]FEPPA PET
findings in stroke. An interaction between region and ET1 suggested that TSPO
immunohistochemistry concurred with [18F]FEPPA on the finding that ET1 increased TSPO only
in regions near the infarct ([F(9,117) = 27.04, P < 0.0005], three-way ANOVA, Fig. 2.8). In the
infarct, ET1 significantly increased TSPO cell count at day 7 (cells/mm2: saline = 48± 43; ET1 =
555 ± 181; P = 0.014, Mann Whitney U test) and day 28 (cells/mm2: saline = 6 ± 6; ET1 = 307 ±
153; P = 0.025, Mann Whitney U test). Proximal WM (ipsilateral corpus callosum) TSPO cell
count agreed with [18F]FEPPA PET in regards to a day 7 elevation (113 ± 93 cells/mm 2) but
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disagreed by showing no day 28 elevation (5 ± 7 cells/mm2) (Fig. 2.9). Remote WM TSPO cell
counts were low and unaffected by stroke (Figs 2.9 and 2.10). Recognizing that spillover of PET
signal from the infarct into the ipsilateral corpus callosum might indicate an increased uptake in
[18F]FEPPA PET when there is no TSPO overexpression, we used TSPO immunohistochemistry
for further comparison of TSPO with GFAP, iNOS, and MHCII.

50

Fig 2.8 Immunohistochemistry showed that TSPO, but not iNOS, was elevated in the infarct site
of ET1 rats at days 7 and 28 post-stroke. a Representative images of OX6 (MHCII), GFAP, iNOS,
and TSPO in the infarct region (IR) and contralateral to the IR (CIR) post-stroke at day 7 and day
28 in saline and ET1 rats. b Quantification of cell count for TSPO and % area coverage for iNOS.
Bar indicates 1 mm in large images and 100 µm in TSPO. Error = SD
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Fig 2.9 TSPO Immunohistochemistry of WM at day 7 and day 28 in saline and ET1 rats. (A)
Representative images and (B) quantification of cell count for TSPO. FM, Forceps Minor; CC,
corpus callosum; i, ipsilateral; c, contralateral; p, posterior. Bar indicates 100 µm. Error = SD
2.3.5 GFAP and iNOS Expression was not Changed in WM Following ET1-induced Stroke
GFAP and iNOS immunohistochemistry were performed to further investigate changes in
astrocytes and microglia as these markers are often compared with TSPO [20,21]. GFAP signal
showed a day 7 border around the infarct and a day 28 scar in ET1 rats, but there were no significant
effects in WM (P = ns, three-way ANOVA, Fig. 2.10). iNOS signal showed sensitivity to ET1
only in the infarct (% area: day 7 = 1.84 ± 2.16; day 28 = 4.74 ± 5.65; P = ns), without significance,
and was not elevated in WM (P = ns, three-way ANOVA) (Figs. 2.8 and 2.10). Overall, GFAP
and iNOS concurred with TSPO immunohistochemistry, with no significant changes in remote
WM following ET1-induced stroke.
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Fig 2.10 WM immunohistochemistry in the contralateral corpus callosum (CC c) showing that at
28 days post-stroke, ET1 rats only showed an elevation of OX6 (MHCII); not TSPO, iNOS, and
GFAP. a Representative images and b quantification of cell count for TSPO and % area coverage
for other markers. Bar indicates 100 µm. Error = SD
2.3.6 MHCII-Positive Activated Microglia were Chronically Expressed in Remote WM
Following ET1-induced Stroke
Immunohistochemistry of the MHCII rat antigen OX6 was used to confirm previous findings by
our group of an ET1-induced increase of remote WM MHCII positive microglia activation (Fig.
2.10) [14,15]. WM OX6 signal was significantly affected by an interaction between timepoint and
ET1 [F(1,15) = 9.73, P = 0.007, three-way ANOVA]. Although there were no significant
interactions with region, we separately analyzed the contralateral corpus callosum at day 28 and
found a significant effect of ET1 (% area saline = 0.62 ± 0.38, ET1 = 4.30 ± 2.83; P = 0.029, Mann
Whitney U test). This indicated that by day 28 post-stroke, MHCII was the only marker to show
sensitivity to ET1 in WM.
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2.4 Discussion
Literature about the non-specificity of TSPO to activated microglia is growing, but there are few
reports showing that TSPO does not colocalize with all activated microglia or is not as sensitive
as MHCII [22–24]. We found that [18F]FEPPA PET did not capture the expected increase of
diffuse, chronically activated MHCII microglia in WM of TgAPP21 rats. Additionally, in an ET1induced subcortical stroke model, MHCII microglia in remote WM were not detectable by
[18F]FEPPA PET or TSPO immunohistochemistry.
The cerebellum was found to be an appropriate pseudoreference region. Other rodent AD
studies have shown that the cerebellum is an acceptable pseudoreference region by demonstrating
a lack of group effect on SUV [25]. When multiple pseudoreference regions are assessed in stroke,
if the group effect is null for multiple regions, preference is sometimes given to the region with
the lowest uptake [26]. Although SUV was lower in the periaqueductal gray and region
contralateral to the infarct, we found that calculating UR using the cerebellum provided better
correlations with TSPO immunohistochemistry and between DV and DVR. Using the cerebellum
also ensured that our WM ROIs are sufficiently distant, thereby minimizing bias caused by partial
volume effects. All of this suggests that the cerebellum is a practical pseudoreference for rodent
TSPO PET studies of stroke and AD, but others should continue to investigate and validate their
choice.
Although an increase in uptake of TSPO tracers in the infarct has been well documented,
to our knowledge, rodent studies have only investigated cortical strokes as opposed to subcortical
strokes [20,23,24,26]. In our study, we found that ET1-induced subcortical stroke infarcts have
increased TSPO uptake at days 7 and 28 post-stroke. The proportion of TSPO signal from
astrocytes cannot be deduced without multilabel immunofluorescence, but the formation of a
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GFAP-positive astrocyte scar between days 7 and 28 suggests a change in astrocyte function that
might explain why in other studies, TSPO expression tends to increase in astrocytes with time after
a stroke [20,23,24]. Similarly, microglial functions seem to change as proinflammatory markers
differ longitudinally; after day 7, some proinflammatory markers decrease while others, including
iNOS, increase [27]. Our study similarly demonstrated that after day 7, iNOS increased while
TSPO decreased, albeit insignificant partly due to high variability in rodent post-stroke iNOS
expression [28]. For these reasons, TSPO PET may not provide unequivocal, longitudinal
measurements for guiding subject-specific infarct-targeted anti-inflammatory therapy after stroke
in rodent models.
Our findings suggest that TSPO does not capture diffuse WM inflammation in the
TgAPP21 model or remote WM inflammation in the ET1-induced subcortical stroke model. WM
TSPO studies in rodents have been restricted to mouse models of multiple sclerosis, which have
focally elevated TSPO in active demyelinating lesions [29]. In the current study, prodromal AD
TgAPP21 rats did not take up more [18F]FEPPA in WM, despite having previously demonstrated
diffuse WM MHCII activated microglia [12]. Similarly, in ET1-induced subcortical stroke, WM
TSPO expression was only increased in regions with focal inflammation and not in regions with
diffuse inflammation. To our knowledge, TSPO overexpression in rodent WM without a nearby
lesion has yet to be demonstrated.
TSPO mismatch with MHCII might be dependent on whether the pathology is associated
with antigens that would induce the antigen-presenting function of MHCII in microglia. When
antigens are not expected to induce pathology, TSPO is overexpressed without MHCII, as was
shown in a rat model of alcohol-induced neurodegeneration [30]. Conversely, when lesions are
present with antigenic alpha-synuclein, as in cases of human multiple system atrophy, post-mortem
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tissue had a 6-fold increase in MHCII and 2-fold increase in TSPO relative to controls [22]. Our
work in rats demonstrates that although TSPO detected neuroinflammation near the ET1-induced
infarct, only MHCII was able to detect the WM microglial activation that occurred late post-stroke
or in response to overexpression of pathogenic APP. Although this makes MHCII a desirable target
for PET, its many genetic variants may pose a challenge.
This study has two main limitations. First, rat WM is small and susceptible to limits in PET
resolution and sensitivity. To overcome this limitation, we used TSPO immunohistochemistry in
rats injected with ET1 or saline to validate that TSPO is not sensitive to WM MHCII activated
microglia. Second, this study used only males to minimize variables as females differ in their
TSPO expression and neuroinflammatory response [31]. Whether males and females differ in their
TSPO expression at an infarct or in WM should be further investigated.
In conclusion, we found that an ET1-induced subcortical stroke increases TSPO
expression. More importantly, WM microglia only expressed TSPO near an ET1-induced lesion,
thereby revealing that TSPO was insensitive to MHCII activated microglia in remote WM and in
WM of prodromal AD rats without a lesion. An MHCII radiotracer would enable longitudinal
imaging of chronically activated MHCII microglia in neurodegenerative diseases.
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Chapter 3: Conclusion and Future Directions
3.1 Summary
In the introduction, the importance of WM in neuronal networks and the definition of inflammation
were briefly discussed to provide background about WM inflammation, particularly WM
microglial activation. The associations between WM disease and microglial activation in
subcortical stroke and AD, along with their main pathologies, were also described. This was
followed by a discussion of methods that can be used to measure WM microglial activation, with
emphasis on TSPO-PET as the focus of this thesis. Importantly, the current thesis was motivated
by the longitudinal ability of TSPO to mark microglial activation and our findings of cognitive
impairment along with chronic microglial activation as detected my MHCII IHC in rat models of
subcortical stroke and prodromal AD.
Our objectives and findings were:
1. Objective: To investigate WM microglial activation in a rat model of prodromal AD with
TSPO-PET using the 2nd generation TSPO-PET radiotracer, [18F]FEPPA.
Finding: TSPO expression, as measured by [18F]FEPPA uptake ratio to cerebellum, was not
elevated in the corpus callosum or forceps minor of a Fischer 344 rat mutated to overexpress
a pathogenetic form of APP.
2. Objective: To investigate WM microglial activation longitudinally in a rat model of
subcortical stroke with TSPO-PET.
Finding: TSPO expression, as measured by [18F]FEPPA uptake ratio to cerebellum, was not
elevated in the corpus callosum or forceps minor of a Fischer 344 rat with subcortical stroke
induced in the dorsal striatum by injection with the vasoconstrictor endothelin-1.
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3. Objective: To investigate and validate WM TSPO expression in a rat model of subcortical
stroke at 7-days and 28-days using IHC.
Finding: TSPO expression at 7-days and 28-days post-stroke, as measured by cell counting on
IHC, was not elevated in the corpus callosum or forceps minor of a Fischer 344 rat with
subcortical stroke induced in the dorsal striatum by injection with the vasoconstrictor
endothelin-1.
4. Objective: To investigate WM microglial activation in a rat model of subcortical stroke using
MHCII, iNOS, and GFAP IHC at 7-days and 28-days post-stroke.
Finding: The only elevated percent area measurement was that of MHCII at 28-days poststroke in corpus callosum and forceps minor that were remote from the stroke site in a Fischer
344 rat with subcortical stroke induced in the dorsal striatum by injection with the
vasoconstrictor endothelin-1.
5. Objective: To compare TSPO-PET and TSPO IHC to MHCII IHC in WM.
Finding: In a Fischer 344 rat model of subcortical stroke by endothelin-1, MHCII IHC showed
chronic (28-days post-stroke) diffuse WM microglial activation in remote corpus callosum
while TSPO-PET and TSPO IHC only showed WM microglial activation that was acute (7days post-stroke) and proximal to a lesion.
The implications of these findings were discussed amongst others in chapter 2, but the main
finding was that TSPO expression was not able to detect the chronic microglial activation in WM
that is detectable by MHCII IHC. The implications of this finding are further discussed in the
follow two sections.
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3.2 TSPO in WM
Despite differences in TSPO expression between rats and humans, our findings may offer insight
into studies investigating WM microglial activation with TSPO PET in human AD and subcortical
stroke. In particular, our finding that TSPO was only overexpressed in the infarct and in WM near
the infarct may help explain the disagreement between human AD studies. For example, a study
by Kreisl et al. showed that WM TSPO uptake was similar between healthy controls, patients with
mild cognitive impairment, and AD but did not report lesions [1]. Conversely, a study by Suridjan
et al. showed higher TSPO uptake in AD patients with lesions [2]. It is therefore possible that the
disagreement may be attributed to the presence of lesions. Furthermore, the current findings may
help explain why after subcortical stroke, remote WM uptake of the TSPO radiotracer
[11C]PK11195 was elevated in patients with an infarct directly in the pyramidal tract while it was
unaffected in patients with an infarct near a WM tract [3]. It is possible that the former induces a
WM lesion by Wallerian degeneration with a severe inflammatory response and TSPO expression
while the latter may not induce a lesion but, as we demonstrated in rats, it induces a delayed MHCII
microglial activation with no TSPO expression. This cannot be confirmed as these patients were
only tested for motor function and followed for 6 months after a stroke, however, the effects of
subcortical stroke on cognitive impairment and dementia usually appear years later [4]. Overall,
our findings suggest that the disagreement between human AD studies investigating WM
microglial activation with TSPO-PET may be explained by the presence of lesions and that
subcortical strokes that are not directly in a WM tract may not show WM microglial activation on
[11C]PK11195 PET because the damage is not severe enough to be associated with TSPO
expression.
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3.3 MHCII as a Marker of Microglial Activation
Although MHCII can be elevated in lesions, it can also be expressed without lesions. An example
of a lesion where an elevated expression of MHCII has been often observed is senile plaques in
people with AD [5]. On the other hand, non-lesion nonhuman primate studies where variation and
risk factor factors were minimized demonstrated that the expression of MHCII increases with
aging [6]. More recently, studies have shown that MHCII expression increases with aging
specifically in the WM [7]. Overall, the expression of MHCII near senile plaques in people with
AD, their increase with aging, and their increase with aging in WM suggest MHCII expression
does not discriminate based on the presence of a lesion.
3.4 Limitations
3.4.1 Fischer 344 rat strain may have an overactive inflammatory response
An additional limitation of the study was the exclusive usage of the Fischer 344 rat strain, which
may have an overactive chronic inflammatory response. Relative to the Sprague Dawley and Lewis
rat strains, the Fischer 344 rats have a minimal ability to habituate; when Fischer 344 rats are
repeatedly exposed to a stress, their stress response does not decrease in magnitude [8].
Additionally, a low habituation corresponds to an overactive chronic inflammatory response [9].
It is therefore possible that Fischer 344 rats have an overactive inflammatory response. Although
other rat models may have a reduced MHCII microglial activation response to stroke or a TgAPP21
genotype, it is well known that MHCII microglial activation can be seen in human AD [5,7]. This
suggests that human MHCII microglial activation may be modeled well by Fischer 344 rats.
3.4.2 Gray Matter in Subcortical Stroke and AD
Although there may be interest in the clinical importance of inflammation in the gray matter, we
do not expect to find any significant inflammatory effects in the gray matter of our models, and
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we therefore did not analyze all available gray matter regions using [18F]FEPPA PET. To our
knowledge, clinical studies of subcortical stroke have not reported microglial activation in gray
matter outside the infarct site [3]. Similarly, clinical studies of AD only report brain microglial
activation at sites of amyloid deposition, which are restricted to the neocortex and hippocampus
[5,10–14]. For our models, we do not expect significant inflammatory effects in the gray matter
because we observed, using immunohistochemistry, that (i) MHCII expression was much greater
in the white matter regions than the gray matter regions and (ii) TSPO expression was not elevated
in gray matter, except for at the injection site in some rats (data not shown). Specifically for the
subcortical stroke model, this is in concordance with the clinical literature and our previous
findings that a rat subcortical stroke does not lead to microglial overactivation in remote gray
matter, although the stroke was thalamic instead of striatal [15]. As for the AD model, our current
observations agree with our previous studies and make sense because the model is known to not
deposit amyloid unless there is severe cerebral stress such as encephalitis [16–18]. Because we did
not observe any gray matter inflammation previously in extensive studies or in the
immunohistochemistry of this study, in vivo segmentation of gray matter was omitted from our
methods and therefore analysis.
3.5 Future Directions
3.5.1 MHCII radiotracers
As stated in chapter 2, a future direction to pursue is the development of MHCII radiotracers, but
this comes with challenges. To make accurate statements about MHCII molecules, a brief review
of MHC nomenclature is necessary. The term MHC comes from George Davis Snell’s discovery
that the success of tissue transplants depends on genetically-determined histocompatibility [19].
This histocompatibility comes from a set of immune molecules that are genetically encoded by
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what the peer-reviewed literature now refers to as the MHC, which in humans has 224 genes [20].
These MHC genes include those that encode for three distinct classes of immune molecules: MHCI
for innate immunity, MHCII for adaptive immunity, and MHCIII for other molecules with a
variety of functions (Fig. 3.1). While MHCIII gene products are only referred to as molecules,
MHCI and MHCII gene products are interchangeably referred to as molecules and glycoproteins
because the finished proteins have many complex carbohydrates groups [21]. MHC nomenclature
is further complicated by how MHC, MHCI, MHCII, and MHCIII are only hypernyms. For
example, MHC molecules in humans and rats are referred to as human leukocyte antigens (HLA)
and RT1 (no full form) respectively [22] (Fig. 3.1). Overall, these facts suggest that care is required
when referring to the MHC or its molecules.

Fig 3.1 A visual summary of MHC nomenclature. MHC refers to the gene complex containing
genes that encode the protein components of the three molecule classes: MHCI, MHCII, and
MHCIII. Each of these classes has many molecules, which may be individually named according
to the species (HLA in humans) for a variety of other reasons
With some genes in the MHC having over 500 alleles, the MHC is the most polymorphic
region with phenotypic consequences in vertebrates [23]. In fact, the literature recognizes over 479
MHC-related traits [24]. This is largely thought to have evolved for the sake of maintaining a
diverse set of immune responses in populations [23]. On the other hand, some of these traits include
diseases that are associated with autoimmune pathology such as narcolepsy, rheumatoid arthritis,
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type 1 diabetes mellitus, and AD [24,25]. In other words, although genetic mutations in the MHC
may have led to a stronger immunity and population survival, many mutations led to disease.
Differences in MHCII genes and molecular expression are pathologically important. For
example, some MHCII genes are associated with disease; over 90% of human autoimmune
diseases are associated with the presence of these three MHCII allele combinations: HLADQ2/DR3, HLA-DQ6/DR2, and HLA-DQ8/DR4 [26]. Differences in molecular expression of
MHCII have been observed in a variety of neurological pathologies, including schizophrenia,
multiple sclerosis, multiple system atrophy, neuromyelitis optica, myasthenia gravis, Parkinson’s
disease, and AD [27–30]. Overall, MHCII molecules are a compelling target for the quantification
of differences because of the association between MHCII expression and neurodegenerative
diseases, and the occurrence of autoimmune diseases in people with specific MHCII gene
combinations.
Although the polymorphism of MHCII poses a challenge, there may be representative
targets without polymorphism. The polymorphism poses a challenge because differences in protein
structure could make it unlikely for radioligands to bind every structure with a high enough affinity
for PET imaging. Instead, there are representative targets without polymorphism including (i) the
alpha chains in MHCII molecules, which are made up of an alpha chain and beta chain, (ii) the
gamma chain, which transiently associates with many MHCII molecules during their folding and
transport [20]. The alpha chain of HLA-DR is an exciting candidate because the alpha chain
structure has been elucidated by high-resolution X-ray-crystallography (search on Uniprot, ID:
P01903), there are several molecules known to interact with the alpha chain (also Uniprot), the
sequence identity of humans has a 77% match with that of rats (Fig. 3.2), and HLA-DR indicates
pathology according to post-mortem AD IHC studies [5,7]. Overall, MHCII polymorphism could

68
hinder radioligand binding, but there are alternative exciting targets with minimal or no
polymorphism such as the HLA-DR alpha chain.

Fig 3.2 HLA-DR alpha chain alignment between humans and rats. The human HLA-DR alpha
subunit has an identical 77% match with the laboratory rat species, Rattus norvegicus. The human
HLA-DR alpha subunit, P01903, was set as a query with the algorithm set to search for the top
1000 matches on the NCBI blast website protein-protein (blast.ncbi.nlm.nih.gov). One of the
matches, here shown as “Sbjct”, was the rat variant. The numbers flanking each row indicate the
count of the amino acid. The middle row indicates the matching results: identical matches are
echoed, non-matches are blank, and non-matches that are chemically similar are indicated with a
positive sign positive (+)

3.5.2 Alzheimer’s Disease and Subcortical Stroke Comorbidity
Another direction to pursue is the comorbidity of subcortical stroke and AD because it increases
the occurrence of dementia and, potentially, WM microglial activation. A heightened dementia
occurrence has been attributed to subcortical stroke and AD comorbidity by the Nun study, which
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demonstrated that a dementia diagnosis was not independently increased by the presence of brain
infarcts, but the prevalence of dementia in those with AD pathology increased from 57% to 93%
if they also had a subcortical infarct [31]. A recent hypothesis-generating paper has attributed this
interaction to persistent post-stroke WM microglial activation as detected by [11C]PK11195-PET
[3]. Overall, the nun study findings of increased dementia when AD neuropathology is combined
with subcortical stroke and the attribution of cognitive decline to WM microglial activation suggest
that the comorbidity is a worthwhile direction to investigate.
Despite the increased occurrence of dementia when AD pathology is combined with
subcortical stroke, very few large studies distinguish subcortical stroke from overall stroke [32,33].
These large studies will be necessary to gain a more representative understanding of their
comorbidity.
3.5.3 Using PET to Guide WM Microglial Activation Therapy
TSPO-PET and, if developed, MHCII-PET, may be used to guide therapeutics that target
microglial activation. PET is powerful in this regard because it allows microglial activation to be
imaged longitudinally and in living people. By doing so, investigators can determine if therapeutics
have an effect on microglial activation in WM of living people, the optimal dose, and whether the
therapeutics have an optimal therapeutic window. For example, in AD, cholinesterase inhibitors
such as Donepezil have been shown to be beneficial only when AD is mild or moderate [34]. In
ischemic stroke, the field has recently been able to use in vivo imaging techniques, specifically
diffusion-weighted MRI and perfusion CT, to extend the therapeutic window to 24 hours for which
thrombectomy is beneficial [35]. By targeting WM microglial activation instead, it may be possible
to slow the progression of or prevent chronic neurological and cognitive decline.
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In particular, an MHCII radiotracer would be able to guide therapeutic approaches that
target WM MHCII microglial activation for AD and chronic timepoints after subcortical stroke. It
may also be used to guide therapeutics for some of the other neurodegenerative diseases that, as
mentioned in a previous section, are associated with abnormal MHCII expression such as multiple
sclerosis. Although TSPO-PET may not be able to guide therapeutics that target MHCII microglial
activation, it may still be used to guide other types of microglial activation. For example, TSPOPET was certainly able to detect the microglial and astrocyte activation that occured in the infarct
of the subcortical stroke.
3.6 Conclusion
The most significant finding of this study was that TSPO was unable to mark important
pathology in the WM in rat models of subcortical stroke and AD. Because of this important
finding, there is a strong case to be made for the development of MHCII radiotracers. One
promising MHCII radiotracer target might be the MHCII HLA-DR alpha chain. If developed, it
may be able to guide therapeutic approaches targeting WM inflammation. Furthermore, TSPOPET may be used to guide therapeutic approaches that target the microglial and astrocyte
activation that occurs in the infarct of the subcortical stroke. Additionally, TSPO-PET may also
be used to image WM microglial activation that occurs after subcortical stroke that occurs
directly in a WM target.

71
3.7 References
1. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein
correlates with severity of Alzheimer’s disease. Brain. 2013;136:2228-2238.
2. Suridjan I, Pollock BG, Verhoeff NPLG, et al. In-vivo imaging of grey and white matter
neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a
novel radioligand, [18F]-FEPPA. Mol Psychiatry. 2015;20:1579-1587.
3. Thiel A, Radlinska BA, Paquette C, et al. The temporal dynamics of poststroke
neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11CPK11195 in acute subcortical stroke. J Nucl Med. 2010;51:1404-1412.
4. Norrving B. Long-term prognosis after lacunar infarction. Lancet Neurol. 2003;2:238-245.
5. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile
dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLADR. Neurosci Lett. 1987;79:195-200.
6. Sheffield LG, Berman NEJ. Microglial Expression of MHC Class II Increases in Normal
Aging of Nonhuman Primates. Neurobiol Aging. 1998;19:47-55.
7. Raj D, Yin Z, Breur M, et al. Increased White Matter Inflammation in Aging- and
Alzheimer’s Disease Brain. Front Mol Neurosci. 2017;10:206.
8. Dhabhar FS, McEwen BS, Spencer RL. Adaptation to Prolonged or Repeated Stress –
Comparison between Rat Strains Showing Intrinsic Differences in Reactivity to Acute Stress.
Neuroendocrinology. 1997;65:360-368.
9. Thoma MV, Gianferante D, Hanlin L, Fiksdal A, Chen X, Rohleder N. Stronger
hypothalamus-pituitary-adrenal axis habituation predicts lesser sensitization of inflammatory
response to repeated acute stress exposures in healthy young adults. Brain Behav Immun.
2017;61:228-235.
10. Hyman BT, Trojanowski JQ. Editorial on Consensus Recommendations for the Postmortem
Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan
Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of
Alzheimer Disease. J Neuropathol Exp Neurol. 1997;56:1095-1097.
11. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s
Association guidelines for the neuropathologic assessment of Alzheimer’s disease.
Alzheimers Dement. 2012;8:1-13.
12. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol
Aging. 2001;22:799-809.
13. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer
disease: The last 12 years. J Alzheimers Dis. 2006;9:271-276.

72
14. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced
by activated microglia. Nature. 2017;541:481-487.
15. Weishaupt N, Riccio P, Dobbs T, Hachinski VC, Whitehead SN. Characterization of
Behaviour and Remote Degeneration Following Thalamic Stroke in the Rat. Int J Mol Sci.
2015;16:13921-13936.
16. Levit A, Allman BL, Nagalingam R, Hachinski V, Whitehead S. Age-dependent white
matter inflammation and cognitive impairment in the TgAPP21 rat model of Alzheimer
disease. Neurology. 2018;91:242-242.
17. Weishaupt N, Liu Q, Shin S, et al. APP21 transgenic rats develop age-dependent cognitive
impairment and microglia accumulation within white matter tracts. J Neuroinflammation.
2018;15:241.
18. Rosen RF, Fritz JJ, Dooyema J, et al. Exogenous seeding of cerebral β-amyloid deposition in
βAPP-transgenic rats. J Neurochem. 2012;120:660-666.
19. Hull P. Notes on DR Snell’s observations concerning the H-2 Locus polymorphism.
Heredity. 1970;25:461-465.
20. The MHC sequencing consortium. Complete sequence and gene map of a human major
histocompatibility complex. Nature. 1999;401:921-923.
21. Ryan SO, Cobb BA. Roles for major histocompatibility complex glycosylation in immune
function. Semin Immunopathol. 2012;34.
22. Günther E, Walter L. The major histocompatibility complex of the rat (Rattus norvegicus).
Immunogenetics. 2001;53:520-542.
23. Piertney SB, Oliver MK. The evolutionary ecology of the major histocompatibility complex.
Heredity. 2006;96:7-21.
24. Clark PM, Kunkel M, Monos DS. The dichotomy between disease phenotype databases and
the implications for understanding complex diseases involving the major histocompatibility
complex. Int J Immunogenet. 2015;42:413-422.
25. Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals
identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452-1458.
26. Mangalam AK, Rajagopalan G, Taneja V, David CS. HLA Class II Transgenic Mice Mimic
Human Inflammatory Diseases. In: Advances in Immunology. Vol 97. Academic Press;
2008:65-147.
27. Tong J, Williams B, Rusjan PM, et al. Concentration, distribution, and influence of aging on
the 18 kDa translocator protein in human brain: Implications for brain imaging studies. J
Cereb Blood Flow Metab. June 2019:271678X19858003.

73
28. Durrenberger PF, Fernando FS, Kashefi SN, et al. Common mechanisms in
neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray
study. J Neural Transm. 2015;122:1055-1068.
29. Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL. Narcolepsy: autoimmunity,
effector T cell activation due to infection, or T cell independent, major histocompatibility
complex class II induced neuronal loss? Brain J Neurol. 2010;133:1300-1311.
30. Misra MK, Damotte V, Hollenbach JA. The immunogenetics of neurological disease.
Immunology. 2018;153:399-414.
31. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain
infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA.
1997;277:813-817.
32. Honig LS, Tang M-X, Albert S, et al. Stroke and the Risk of Alzheimer Disease. Arch
Neurol. 2003;60:1707-1712.
33. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy
confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre.
Brain. 2013;136:2697-2706.
34. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database
Syst Rev. 2018;18:CD001190.
35. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with
a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378:11-21.

74
Appendices
Appendix A: Example Logan Solution
The Logan solution for a 2TCM may be derived using the equation defining the compartments in
a tissue region as measured on pet (Eq1a), its integration (Eq1b), and the first-order kinetic
equations for the exchange of radiotracer in the nondisplaceable compartment (Eq2) and bound
compartment (Eq3).
𝐶𝑇 (𝑡) = 𝐶1 (𝑡) + 𝐶2 (𝑡) + 𝑉𝑏 𝐶 𝐵 (𝑡)

Eq 1a:
𝑡

𝑡

𝑡

𝑡

∫0 𝐶𝑇 (𝑢) 𝑑𝑢 = ∫0 𝐶1 (𝑢) 𝑑𝑢 + ∫0 𝐶2 (𝑢) 𝑑𝑢 + 𝑉𝑏 ∫0 𝐶 𝐵 (𝑢) 𝑑𝑢

Eq 1b:

𝑑𝐶1 (𝑡)

Eq 2:

𝑑𝑡

= 𝐾1 𝐶𝑝 (𝑡) − 𝑘2 𝐶1 (𝑡) − 𝑘3 𝐶1 (𝑡) + 𝑘4 𝐶2 (𝑡)
𝑑𝐶2 (𝑡)

Eq 3:

𝑑𝑡

= 𝑘3 𝐶1 (𝑡) − 𝑘4 𝐶2 (𝑡)

Where for reversible tracer binding in a 2TCM:
𝑉𝑇 =

𝐾1
𝑘2

(1 +

𝑘3
𝑘4

)

𝐶𝑇 = Concentration of total radioactivity in the tissue
𝐶𝑝 = Concentration of free parent metabolite in the plasma
𝐶𝑏 = Concentration of total radioactivity in whole blood
𝐶1 = Concentration of parent metabolite in the nondisplaceable compartment
𝐶2 = Concentration of parent metabolite in the bound compartment
𝑉𝑏 = The ROI volume fraction of vascular tissue
𝐾1 = plasma-to-unbound-compartment transfer rate (delivery)
𝑘2 = unbound-compartment-to-plasma transfer rate (clearance)
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𝑘3 = unbound-compartment-to-bound-compartment transfer rate (binding)
𝑘4 = bound-compartment-to-unbound-compartment transfer rate (unbinding)
The approach here is to express the integrals in equation 1b in terms of known variables. To do
this, first derive simple expressions for the integrals.
𝑡

For ∫0 𝐶1 (𝑢) 𝑑𝑢, differentiate equation 1a, substitute in equations 2 and 3 and simplify, integrate,
then rearrange:
𝑑𝐶𝑇 (𝑡)
𝑑𝐶1 (𝑡) 𝑑𝐶2 (𝑡)
𝑑𝐶𝐵 (𝑡)
=
+
+ 𝑉𝑏
𝑑𝑡
𝑑𝑡
𝑑𝑡
𝑑𝑡
𝑑𝐶𝑇 (𝑡)
𝑑𝐶𝐵 (𝑡)
= 𝐾1 𝐶𝑝 (𝑡) − 𝑘2 𝐶1 (𝑡) + 𝑉𝑏
𝑑𝑡
𝑑𝑡
𝑡

𝑡

𝑡

𝐶𝑇 (𝑡) = 𝐾1 ∫ 𝐶𝑝 (𝑢)𝑑𝑢 − 𝑘2 ∫ 𝐶1 (𝑢)𝑑𝑢 + 𝑉𝑏 ∫ 𝐶𝐵 (𝑢)𝑑𝑢
0
𝑡

∫ 𝐶1 (𝑢)𝑑𝑢 =
0

0

0

𝑡
𝑡
1
[𝐾1 ∫ 𝐶𝑝 (𝑢)𝑑𝑢 − 𝐶𝑇 (𝑡) + 𝑉𝑏 ∫ 𝐶𝐵 (𝑢)𝑑𝑢 ]
𝑘2
0
0

𝑡

For ∫0 𝐶2 (𝑢) 𝑑𝑢, integrate equation 3 then rearrange:
𝑡

𝑡

𝐶2 (𝑡) = ∫ 𝑘3 𝐶1 (𝑢)𝑑𝑢 − ∫ 𝑘4 𝐶2 (𝑢)𝑑𝑢
0

0

𝑡

𝑡
1
∫ 𝐶2 (𝑢)𝑑𝑢 = [∫ 𝑘3 𝐶1 (𝑢)𝑑𝑢 − 𝐶2 (𝑡)]
𝑘4 0
0

Now the integrals may be substituted into equation 1b and expanded before resubstituting in
𝑡

∫0 𝐶1 (𝑢)𝑑𝑢 again:

76
𝑡

𝑡
𝑡
𝑡
1
1
∫ 𝐶𝑇 (𝑢) 𝑑𝑢 = [𝐾1 ∫ 𝐶𝑝 (𝑢)𝑑𝑢 − 𝐶𝑇 (𝑡) + 𝑉𝑏 ∫ 𝐶𝐵 (𝑢)𝑑𝑢 ] +
[∫ 𝑘 𝐶 (𝑢)𝑑𝑢 − 𝐶2 (𝑡)]
𝑘2
𝑘4 0 3 1
0
0
0
𝑡

+ 𝑉𝑏 ∫ 𝐶 𝐵 (𝑢) 𝑑𝑢
0
𝑡

𝑡
𝐾1 𝑡
𝐶𝑇 (𝑡)
1
𝑘3 𝑡
𝐶2 (𝑡)
∫ 𝐶𝑇 (𝑢) 𝑑𝑢 = ∫ 𝐶𝑝 (𝑢)𝑑𝑢 −
+ 𝑉𝑏 ∫ 𝐶𝐵 (𝑢)𝑑𝑢 +
∫ 𝐶1 (𝑢)𝑑𝑢 −
𝑘2 0
𝑘2
𝑘2
𝑘4 0
𝑘4
0
0
𝑡

+ 𝑉𝑏 ∫ 𝐶 𝐵 (𝑢) 𝑑𝑢
0
𝑡

𝑡
𝑡
𝐾1 𝑡
𝐶𝑇 (𝑡)
1
𝑘3 1
∫ 𝐶𝑇 (𝑢) 𝑑𝑢 = ∫ 𝐶𝑝 (𝑢)𝑑𝑢 −
+
𝑉 ∫ 𝐶 (𝑢)𝑑𝑢 +
[𝐾 ∫ 𝐶 (𝑢)𝑑𝑢
𝑘2 0
𝑘2
𝑘2 𝑏 0 𝐵
𝑘4 𝑘2 1 0 𝑝
0
𝑡

− 𝐶𝑇 (𝑡) + 𝑉𝑏 ∫ 𝐶𝐵 (𝑢)𝑑𝑢 ] −
0

𝑡
𝐶2 (𝑡)
+ 𝑉𝑏 ∫ 𝐶 𝐵 (𝑢) 𝑑𝑢
𝑘4
0

This can then be expanded and rearranged into the linear equation:
𝑡

𝑡
𝐾1
𝑘3
1
𝑘3
∫ 𝐶𝑇 (𝑢) 𝑑𝑢 = (1 + ) ∫ 𝐶𝑝 (𝑢)𝑑𝑢 − (1 + ) 𝐶𝑇 (𝑡)
𝑘2
𝑘4 0
𝑘2
𝑘4
0

+ 𝑉𝑏 (1 +

𝑡
1
𝑘3
1
) ∫ 𝐶𝐵 (𝑢)𝑑𝑢 − ( ) 𝐶2 (𝑡)
+
𝑘2 𝑘4 𝑘2 0
𝑘4

But since 𝐶𝑇 (𝑡) is known, this equation may be made more stable by dividing both sides by 𝐶𝑇 (𝑡):
𝑡

𝑡

𝑡

∫0 𝐶𝑇 (𝑢) 𝑑𝑢
𝐾1
𝑘3 ∫ 𝐶𝑝 (𝑢)𝑑𝑢
1
𝑘3
1
𝑘3 ∫0 𝐶𝐵 (𝑢)𝑑𝑢
)
= (1 + ) 0
− (1 + ) + 𝑉𝑏 (1 + +
𝐶𝑇 (𝑡)
𝑘2
𝑘4
𝐶𝑇 (𝑡)
𝑘2
𝑘4
𝑘2 𝑘4 𝑘2
𝐶𝑇 (𝑡)
1 𝐶2 (𝑡)
−( )
𝑘4 𝐶𝑇 (𝑡)
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Appendix B: Time-activity curves

Figure A.1. Time-activity curves. Representative day-28 post-stroke ET1 rat time-activity curves.
The top row shows the initial phase with its time = 0 s equating to 27 s of the dynamic scan. The
bottom row shows the full dynamic scan. Time-activity curves of the input function from the cavity
of the left ventricle were corrected for the fraction of parent radiotracer that was free in the plasma.
c, contralateral; CC, corpus callosum; CIR, contralateral to the infarct region, FM: Forceps Minor;
i, ipsilateral; IR, infarct region; Lv, left ventricle.
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Appendix C: Animal Use Ethics Approval
From:

eSirius3GWebServer

To:

Shawn Whitehead; Animal Care Committee

Cc:

mgrsmtgs@uwo.ca

Subject:

eSirius3G Notification -- 2018-132 New Protocol Approved

Date:

October-11-18 4:02:35 PM

AUP Number: 2018-132
PI Name: Whitehead, Shawn N
AUP Title: Role of vascular risk factors in cognitive decline
Approval Date: 10/01/2018

Official Notice of Animal Care Committee (ACC) Approval:
Your new Animal Use Protocol (AUP) 2018-132:1: entitled " Role of vascular
risk factors in cognitive decline"
has been APPROVED by the Animal Care Committee of the University Council on
Animal Care. This approval, although valid for up to four years, is subject to
annual Protocol Renewal.
Prior to commencing animal work, please review your AUP with your research
team to ensure full understanding by everyone listed within this AUP.
As per your declaration within this approved AUP, you are obligated to ensure
that:
1) Animals used in this research project will be cared for in alignment
with:
a) Western's Senate MAPPs 7.12, 7.10, and 7.15
http://www.uwo.ca/univsec/policies_procedures/research.html
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b) University Council on Animal Care Policies and related
Animal Care Committee procedures
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies.htm

2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including
permits and scientific/departmental peer approvals, are complete and accurate;
c) any divergence from this AUP will not be undertaken until
the related Protocol Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and Full
AUP Renewals - will be submitted and attended to within timeframes outlined by
the ACC.
e)
http://uwo.ca/research/services/animalethics/animal_use_protocols.html

3) As per MAPP 7.10 all individuals listed within this AUP as having any
hands-on animal contact will
a) be made familiar with and have direct access to this AUP;
b) complete all required CCAC mandatory training
(training@uwo.ca); and
c) be overseen by me to ensure appropriate care and use of
animals.
4) As per MAPP 7.15,
a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to ACVS
Veterinarians and ACC Leaders;
c) UCAC policies and related ACC procedures will be followed,
including but not limited to:
i) Research Animal Procurement
ii) Animal Care and Use Records
iii) Sick Animal Response
iv) Continuing Care Visits
5) As per institutional OH&S policies, all individuals listed within this AUP
who will be using or potentially exposed to
hazardous materials will have completed in advance the appropriate
institutional OH&S training, facility-level training, and reviewed related (M)SDS
Sheets,
http://www.uwo.ca/hr/learning/required/index.html
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Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care

AUC Chair Signature

Dr.Timothy Regnault,
Animal Care Committee Chair

The University of
Western Ontario
Animal Care Committee / University
Council on Animal Care
London, Ontario Canada
N6A 5C1
519-661-2111 x 88792 Fax
519-661-2028
auspc@uwo.ca ï¿½
http://www.uwo.ca/research/services/animalethics/index.html
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